<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Tilray Brands, Inc.</td><td>I notice you've mentioned "Tilray Brands, Inc." but haven't provided an earnings call transcript to translate. Could you please share the specific transcript content you'd like me to translate into Korean? Once you provide the earnings call text, I'll be happy to translate it while maintaining the financial terminology and professional tone appropriate for Korean-speaking investors.</td></tr>
<tr><td>(NASDAQ:TLRY) Q1 2026 Earnings Call October 9, 2025 8:30 AM EDT<br><br>Company Participants<br><br>Berrin Noorata - Chief Corporate Affairs Officer<br>Irwin Simon - President, CEO & Chairman<br>Carl Merton - CFO & Principal Accounting Officer<br>Lloyd Brathwaite - Chief Information Officer<br>Blair MacNeil - President of Tilray Canada<br><br>Conference Call Participants<br><br>Aaron Grey - Alliance Global Partners, Research Division<br>William Kirk - ROTH Capital Partners, LLC, Research Division<br>Xin Ma - TD Cowen, Research Division<br>Frederico Yokota Gomes - ATB Capital Markets Inc., Research Division<br><br>Presentation<br><br>Operator<br><br>Thank you for joining today's conference call to discuss Tilray Brands' financial results for the first quarter fiscal year 2026 ended August 31, 2025.</td><td>(NASDAQ:TLRY) 2026ë…„ë„ 1ë¶„ê¸° ì‹¤ì ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2025ë…„ 10ì›” 9ì¼ ì˜¤ì „ 8:30 EDT<br><br>ì°¸ì„ì<br><br>ë² ë¦° ëˆ„ë¼íƒ€ - ìµœê³ ê¸°ì—…ì—…ë¬´ë‹´ë‹¹ì„ì›<br>ì–´ìœˆ ì‚¬ì´ë¨¼ - ì‚¬ì¥, CEO ê²¸ íšŒì¥<br>ì¹¼ ë¨¸íŠ¼ - CFO ê²¸ ìˆ˜ì„íšŒê³„ë‹´ë‹¹ì„ì›<br>ë¡œì´ë“œ ë¸Œë˜ìŠ¤ì›¨ì´íŠ¸ - ìµœê³ ì •ë³´ë‹´ë‹¹ì„ì›<br>ë¸”ë ˆì–´ ë§¥ë‹ - í‹¸ë ˆì´ ìºë‚˜ë‹¤ ì‚¬ì¥<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>ì•„ë¡  ê·¸ë ˆì´ - ì–¼ë¼ì´ì–¸ìŠ¤ ê¸€ë¡œë²Œ íŒŒíŠ¸ë„ˆìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ìœŒë¦¬ì—„ ì»¤í¬ - ROTH ìºí”¼í„¸ íŒŒíŠ¸ë„ˆìŠ¤, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì‹  ë§ˆ - TD ì½”ì›¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í”„ë ˆë°ë¦¬ì½” ìš”ì½”íƒ€ ê³ ë©”ìŠ¤ - ATB ìºí”¼í„¸ ë§ˆì¼“ì¸  Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ì˜¤í¼ë ˆì´í„°<br><br>2025ë…„ 8ì›” 31ì¼ ì¢…ë£Œëœ 2026 íšŒê³„ì—°ë„ 1ë¶„ê¸° í‹¸ë ˆì´ ë¸Œëœì¦ˆì˜ ì¬ë¬´ì‹¤ì ì„ ë…¼ì˜í•˜ëŠ” ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>[Operator Instructions]<br><br>I'll now turn the call over to Ms. Berrin Noorata, Tilray Brands' Chief Corporate Officer. Thank you. You may now begin. Berrin Noorata<br>Chief Corporate Affairs Officer<br><br>Thank you, operator, and good morning, everyone. By now, you should have access to the earnings press release, which is available on the Investors section of the Tilray Brands website at tilray.com and has been filed with the SEC and SEDAR. Please note that during today's call, we will be referring to various non-GAAP financial measures that can provide useful information for investors.</td><td>[ìš´ì˜ì ì§€ì¹¨]<br><br>ì´ì œ í‹¸ë ˆì´ ë¸Œëœì¦ˆì˜ ìµœê³ ê¸°ì—…ë‹´ë‹¹ì„ì›ì¸ ë² ë¦° ëˆ„ë¼íƒ€ ì—¬ì‚¬ì—ê²Œ í†µí™”ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì‹œì‘í•˜ì…”ë„ ë©ë‹ˆë‹¤.<br><br>ë² ë¦° ëˆ„ë¼íƒ€<br>ìµœê³ ê¸°ì—…ë‹´ë‹¹ì„ì›<br><br>ìš´ì˜ìë‹˜ ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì„¸ìš”. ì§€ê¸ˆì¯¤ ì—¬ëŸ¬ë¶„ê»˜ì„œëŠ” ì‹¤ì  ë³´ë„ìë£Œì— ì ‘ê·¼í•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì´ ìë£ŒëŠ” tilray.comì˜ í‹¸ë ˆì´ ë¸Œëœì¦ˆ ì›¹ì‚¬ì´íŠ¸ íˆ¬ìì ì„¹ì…˜ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìœ¼ë©°, SECì™€ SEDARì— ì œì¶œë˜ì—ˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ í†µí™”ì—ì„œ íˆ¬ììë“¤ì—ê²Œ ìœ ìš©í•œ ì •ë³´ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ” ë‹¤ì–‘í•œ ë¹„GAAP ì¬ë¬´ì§€í‘œë“¤ì„ ì–¸ê¸‰í•  ì˜ˆì •ì„ì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>However, the presentation of this information is not intended to be considered in isolation or as a substitute for the financial information presented in accordance with GAAP. The earnings press release contains a reconciliation of each non-GAAP financial measure to the most comparable measure prepared in accordance with GAAP. In addition, we will be making numerous forward-looking statements during our remarks and in response to your questions. These statements are based on our current expectations and beliefs and involve known and unknown risks and uncertainties, which may prove to be incorrect.</td><td>ê·¸ëŸ¬ë‚˜ ì´ëŸ¬í•œ ì •ë³´ì˜ ì œì‹œëŠ” ë…ë¦½ì ìœ¼ë¡œ ê³ ë ¤ë˜ê±°ë‚˜ GAAPì— ë”°ë¼ ì œì‹œëœ ì¬ë¬´ì •ë³´ë¥¼ ëŒ€ì²´í•˜ëŠ” ê²ƒìœ¼ë¡œ ê°„ì£¼ë˜ì–´ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤. ì‹¤ì  ë³´ë„ìë£Œì—ëŠ” ê° ë¹„GAAP ì¬ë¬´ì§€í‘œë¥¼ GAAPì— ë”°ë¼ ì‘ì„±ëœ ê°€ì¥ ìœ ì‚¬í•œ ì§€í‘œì™€ì˜ ì¡°ì •í‘œê°€ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì €í¬ëŠ” ë°œí‘œ ì¤‘ê³¼ ì—¬ëŸ¬ë¶„ì˜ ì§ˆë¬¸ì— ëŒ€í•œ ë‹µë³€ì—ì„œ ìˆ˜ë§ì€ ë¯¸ë˜ì „ë§ì§„ìˆ ì„ í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì§„ìˆ ë“¤ì€ ì €í¬ì˜ í˜„ì¬ ê¸°ëŒ€ì™€ ë¯¿ìŒì— ê¸°ë°˜í•œ ê²ƒì´ë©°, ë¶€ì •í™•í•  ìˆ˜ ìˆëŠ” ì•Œë ¤ì§„ ê·¸ë¦¬ê³  ì•Œë ¤ì§€ì§€ ì•Šì€ ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì„ í¬í•¨í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Actual results could differ materially from those described in those forward-looking statements. The text in our earnings press release includes many of the risks and uncertainties associated with such forward-looking statements. Today, we will be hearing from key members of our senior leadership team, beginning with Irwin Simon, Chairman and Chief Executive Officer, who will provide opening remarks and commentary, followed by Carl Merton, Chief Financial Officer, who will review our financial results for the first quarter of fiscal year 2026. And now I'd like to turn the call over to Tilray Brands' Chairman and CEO, Irwin Simon.</td><td>ì‹¤ì œ ê²°ê³¼ëŠ” ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì—ì„œ ì„¤ëª…ëœ ë‚´ìš©ê³¼ í˜„ì €íˆ ë‹¤ë¥¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ ì‹¤ì  ë³´ë„ìë£Œì˜ ë‚´ìš©ì—ëŠ” ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ê³¼ ê´€ë ¨ëœ ë§ì€ ìœ„í—˜ìš”ì†Œì™€ ë¶ˆí™•ì‹¤ì„±ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ë‹¹ì‚¬ ê³ ìœ„ ê²½ì˜ì§„ì˜ ì£¼ìš” êµ¬ì„±ì›ë“¤ë¡œë¶€í„° ë§ì”€ì„ ë“¤ì–´ë³´ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ì–´ìœˆ ì‚¬ì´ë¨¼(Irwin Simon) íšŒì¥ ê²¸ ìµœê³ ê²½ì˜ìê°€ ê°œíšŒì‚¬ì™€ ë…¼í‰ì„ ì œê³µí•˜ê³ , ì´ì–´ì„œ ì¹¼ ë¨¸íŠ¼(Carl Merton) ìµœê³ ì¬ë¬´ì±…ì„ìê°€ 2026 íšŒê³„ì—°ë„ 1ë¶„ê¸° ì¬ë¬´ì‹¤ì ì„ ê²€í† í•´ ë“œë¦´ ì˜ˆì •ì…ë‹ˆë‹¤. ì´ì œ í‹¸ë ˆì´ ë¸Œëœì¦ˆ(Tilray Brands)ì˜ íšŒì¥ ê²¸ CEOì¸ ì–´ìœˆ ì‚¬ì´ë¨¼ì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Irwin Simon<br>President, CEO & Chairman<br><br>Thank you, Berrin, and good morning, everyone, and thank you for being here for our Q1 results. Q1 of fiscal 2026 was a testament to the significant momentum Tilray has built across our businesses over the years. I'm proud to report that our strategic focus is continuing to strengthen our profitability, our balance sheet and leveraging our global platform to drive innovation in Cannabis, Beverage and Wellness and continue to deliver solid results for our shareholders. I want to extend my sincere gratitude to our shareholders for their ongoing support and belief in Tilray's vision.</td><td>ì–´ìœˆ ì‚¬ì´ë¨¼<br>ì‚¬ì¥, CEO ê²¸ íšŒì¥<br><br>ë² ë¦°, ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ëª¨ë‘ ì•ˆë…•í•˜ì„¸ìš”. ì €í¬ 1ë¶„ê¸° ì‹¤ì  ë°œí‘œì— ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. 2026 íšŒê³„ì—°ë„ 1ë¶„ê¸°ëŠ” í‹¸ë ˆì´ê°€ ìˆ˜ë…„ê°„ ì‚¬ì—… ì „ë°˜ì— ê±¸ì³ êµ¬ì¶•í•´ì˜¨ ìƒë‹¹í•œ ëª¨ë©˜í…€ì„ ë³´ì—¬ì£¼ëŠ” ì¦ê±°ì˜€ìŠµë‹ˆë‹¤. ì €í¬ì˜ ì „ëµì  ì§‘ì¤‘ì´ ìˆ˜ìµì„±ê³¼ ì¬ë¬´ìƒíƒœë¥¼ ì§€ì†ì ìœ¼ë¡œ ê°•í™”í•˜ê³ , ê¸€ë¡œë²Œ í”Œë«í¼ì„ í™œìš©í•˜ì—¬ ëŒ€ë§ˆì´ˆ, ìŒë£Œ ë° ì›°ë‹ˆìŠ¤ ë¶„ì•¼ì—ì„œ í˜ì‹ ì„ ì£¼ë„í•˜ë©° ì£¼ì£¼ë“¤ì—ê²Œ ê²¬ê³ í•œ ì„±ê³¼ë¥¼ ì§€ì†ì ìœ¼ë¡œ ì œê³µí•˜ê³  ìˆë‹¤ê³  ìë‘ìŠ¤ëŸ½ê²Œ ë³´ê³ ë“œë¦½ë‹ˆë‹¤. í‹¸ë ˆì´ì˜ ë¹„ì „ì— ëŒ€í•œ ì§€ì†ì ì¸ ì§€ì§€ì™€ ë¯¿ìŒì„ ë³´ë‚´ì£¼ì‹  ì£¼ì£¼ ì—¬ëŸ¬ë¶„ê»˜ ì§„ì‹¬ìœ¼ë¡œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>It is encouraging to see our stock [ regaining ] strength this quarter and return to full NASDAQ compliance. Notably, in the months of August and September, Tilray traded well over 1 billion shares each month, highlighting the tremendous interest in our company and not a lot of companies have 1 billion shares trading on a monthly basis. We sincerely thank our shareholders for their continued confidence in our strategy and their commitment to investing in our company, your belief in our long-term vision and what drives us forward. Now go out there and buy some of our products.</td><td>ì´ë²ˆ ë¶„ê¸°ì— ì €í¬ ì£¼ì‹ì´ ê°•ì„¸ë¥¼ ë˜ì°¾ê³  ë‚˜ìŠ¤ë‹¥ ì™„ì „ ì»´í”Œë¼ì´ì–¸ìŠ¤ë¡œ ë³µê·€í•œ ê²ƒì„ ë³´ë‹ˆ ê³ ë¬´ì ì…ë‹ˆë‹¤. íŠ¹íˆ ì£¼ëª©í•  ì ì€ 8ì›”ê³¼ 9ì›”ì— Tilrayê°€ ë§¤ì›” 10ì–µ ì£¼ ì´ìƒ ê±°ë˜ë˜ì—ˆë‹¤ëŠ” ê²ƒì¸ë°, ì´ëŠ” ì €í¬ íšŒì‚¬ì— ëŒ€í•œ ì—„ì²­ë‚œ ê´€ì‹¬ì„ ë³´ì—¬ì£¼ëŠ” ê²ƒì´ë©°, ì›” ê¸°ì¤€ìœ¼ë¡œ 10ì–µ ì£¼ê°€ ê±°ë˜ë˜ëŠ” íšŒì‚¬ëŠ” ê·¸ë¦¬ ë§ì§€ ì•ŠìŠµë‹ˆë‹¤. ì €í¬ ì „ëµì— ëŒ€í•œ ì§€ì†ì ì¸ ì‹ ë¢°ì™€ ì €í¬ íšŒì‚¬ì— ëŒ€í•œ íˆ¬ì ì˜ì§€ë¥¼ ë³´ì—¬ì£¼ì‹  ì£¼ì£¼ ì—¬ëŸ¬ë¶„ê»˜ ì§„ì‹¬ìœ¼ë¡œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì €í¬ì˜ ì¥ê¸° ë¹„ì „ì— ëŒ€í•œ ì—¬ëŸ¬ë¶„ì˜ ë¯¿ìŒì´ ì €í¬ë¥¼ ì•ìœ¼ë¡œ ë‚˜ì•„ê°€ê²Œ í•˜ëŠ” ì›ë™ë ¥ì…ë‹ˆë‹¤. ì´ì œ ë‚˜ê°€ì„œ ì €í¬ ì œí’ˆë“¤ì„ êµ¬ë§¤í•´ ì£¼ì„¸ìš”.</td></tr>
<tr><td>Notably, during the quarter, we achieved net income of $1.5 million and earnings per share of 0, highlighting our commitment to sustainable growth and operational efficiency. We achieved revenue growth across all our business segments with the exception of the Beverage segment, which we remain flat because of deliberate decisions to optimize our craft beer SKU portfolio under Project 420. Overall, total revenue increased by 5% year-over-year to a Q1 record net revenue of $210 million, fueled by double-digit growth in our Canadian Adult-Use and our International Cannabis business, which delivered 12% and 10% growth respectively.</td><td>íŠ¹íˆ ì´ë²ˆ ë¶„ê¸° ë™ì•ˆ ë‹¹ì‚¬ëŠ” 150ë§Œ ë‹¬ëŸ¬ì˜ ìˆœì´ìµê³¼ ì£¼ë‹¹ìˆœì´ìµ 0ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í•˜ì—¬ ì§€ì†ê°€ëŠ¥í•œ ì„±ì¥ê³¼ ìš´ì˜ íš¨ìœ¨ì„±ì— ëŒ€í•œ ë‹¹ì‚¬ì˜ ì˜ì§€ë¥¼ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. í”„ë¡œì íŠ¸ 420 í•˜ì—ì„œ í¬ë˜í”„íŠ¸ ë§¥ì£¼ SKU í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ìµœì í™”í•˜ê¸° ìœ„í•œ ì˜ë„ì ì¸ ê²°ì •ìœ¼ë¡œ ì¸í•´ ë³€ë™ì´ ì—†ì—ˆë˜ ìŒë£Œ ë¶€ë¬¸ì„ ì œì™¸í•˜ê³ ëŠ” ëª¨ë“  ì‚¬ì—… ë¶€ë¬¸ì—ì„œ ë§¤ì¶œ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì „ì²´ì ìœ¼ë¡œ ì´ ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 5% ì¦ê°€í•˜ì—¬ 1ë¶„ê¸° ê¸°ë¡ì¸ ìˆœë§¤ì¶œ 2ì–µ 1ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ê°ê° 12%ì™€ 10%ì˜ ì„±ì¥ì„ ë‹¬ì„±í•œ ìºë‚˜ë‹¤ ì„±ì¸ìš© ë° êµ­ì œ ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì˜ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We also continue to strengthen our balance sheet by reducing our outstanding debt by $7.7 million this quarter, bringing our net debt-to-EBITDA ratio of 0.7x (sic) [ 0.07x ] cash to and our cash equivalent to $265 million. Our results are underpinned by our deep understanding of product innovation and evolving what consumers prefer. This expertise allows us to shape innovative offerings and not only meet current demand, but anticipate future needs, keeping Tilray at the forefront of the cannabis, beverage and wellness markets.</td><td>ë˜í•œ ì´ë²ˆ ë¶„ê¸°ì— 770ë§Œ ë‹¬ëŸ¬ì˜ ë¶€ì±„ë¥¼ ìƒí™˜í•˜ì—¬ ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ì§€ì†ì ìœ¼ë¡œ ê°•í™”í–ˆìœ¼ë©°, ìˆœë¶€ì±„ ëŒ€ EBITDA ë¹„ìœ¨ì„ 0.07ë°°ë¡œ ë‚®ì¶”ê³  í˜„ê¸ˆ ë° í˜„ê¸ˆì„± ìì‚°ì„ 2ì–µ 6,500ë§Œ ë‹¬ëŸ¬ë¡œ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤ì ì€ ì œí’ˆ í˜ì‹ ì— ëŒ€í•œ ê¹Šì€ ì´í•´ì™€ ì†Œë¹„ì ì„ í˜¸ë„ ë³€í™”ì— ëŒ€í•œ í†µì°°ë ¥ì„ ë°”íƒ•ìœ¼ë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì „ë¬¸ì„±ì„ í†µí•´ í˜ì‹ ì ì¸ ì œí’ˆì„ ê°œë°œí•  ìˆ˜ ìˆìœ¼ë©°, í˜„ì¬ì˜ ìˆ˜ìš”ë¥¼ ì¶©ì¡±í•  ë¿ë§Œ ì•„ë‹ˆë¼ ë¯¸ë˜ì˜ ë‹ˆì¦ˆë¥¼ ì˜ˆì¸¡í•˜ì—¬ Tilrayê°€ ëŒ€ë§ˆì´ˆ, ìŒë£Œ ë° ì›°ë‹ˆìŠ¤ ì‹œì¥ì—ì„œ ì„ ë‘ ìë¦¬ë¥¼ ìœ ì§€í•  ìˆ˜ ìˆë„ë¡ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Today, Tilray owns and operates more than 40 unique brands in over 20 countries, and we are the predominant global cannabis leader trusted by patients, medical professionals and governments in over 20 countries and #1 Canadian cannabis producer by revenue, the fourth largest craft beer producer in the United States and a market leader in branded hemp products across North America with our portfolio of high-protein hemp snacks and better-for-you products, holding nearly a 60% market share and now a leader in the new exciting hemp-derived Delta-9 THC beverages across the U.S. We have built a diversified global platform that is a leader in every industry which we compete.</td><td>í˜„ì¬ TilrayëŠ” 20ê°œêµ­ ì´ìƒì—ì„œ 40ê°œê°€ ë„˜ëŠ” ê³ ìœ  ë¸Œëœë“œë¥¼ ì†Œìœ í•˜ê³  ìš´ì˜í•˜ê³  ìˆìœ¼ë©°, 20ê°œêµ­ ì´ìƒì˜ í™˜ì, ì˜ë£Œ ì „ë¬¸ê°€, ì •ë¶€ë¡œë¶€í„° ì‹ ë¢°ë°›ëŠ” ê¸€ë¡œë²Œ ëŒ€ë§ˆì´ˆ ì—…ê³„ì˜ ì„ ë„ ê¸°ì—…ì…ë‹ˆë‹¤. ë˜í•œ ë§¤ì¶œ ê¸°ì¤€ ìºë‚˜ë‹¤ 1ìœ„ ëŒ€ë§ˆì´ˆ ìƒì‚°ì—…ì²´ì´ì, ë¯¸êµ­ 4ìœ„ ìˆ˜ì œë§¥ì£¼ ìƒì‚°ì—…ì²´ì´ë©°, ê³ ë‹¨ë°± í–„í”„ ìŠ¤ë‚µê³¼ ê±´ê°• ì§€í–¥ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¡œ ê±°ì˜ 60%ì˜ ì‹œì¥ì ìœ ìœ¨ì„ ë³´ìœ í•œ ë¶ë¯¸ ë¸Œëœë“œ í–„í”„ ì œí’ˆì˜ ì‹œì¥ ë¦¬ë”ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì œëŠ” ë¯¸êµ­ ì „ì—­ì—ì„œ ìƒˆë¡­ê³  í¥ë¯¸ì§„ì§„í•œ í–„í”„ ìœ ë˜ ë¸íƒ€-9 THC ìŒë£Œ ë¶€ë¬¸ì˜ ì„ ë„ ê¸°ì—…ì´ê¸°ë„ í•©ë‹ˆë‹¤. ì €í¬ëŠ” ê²½ìŸí•˜ëŠ” ëª¨ë“  ì‚°ì—…ì—ì„œ ë¦¬ë”ì‹­ì„ ë°œíœ˜í•˜ëŠ” ë‹¤ê°í™”ëœ ê¸€ë¡œë²Œ í”Œë«í¼ì„ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Let me briefly review each business. Our Cannabis business, as I said, grew 5% year-over-year to $65 million. Globally, the cannabis industry continues to evolve, and Tilray has the cultivation and manufacturing agility at the right cost to compete and lead in any commercial markets around the world. Recent developments in the U.S. have strengthened our optimism around rescheduling of medical cannabis, and we've seen in other countries -- as we've seen in other countries around the world. We believe rescheduling would enhance our patient access and improve the quality of patient care, promote scientific research and support responsible regulatory framework.</td><td>ê° ì‚¬ì—… ë¶€ë¬¸ì„ ê°„ëµíˆ ê²€í† í•´ë³´ê² ìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ë‹¹ì‚¬ì˜ ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì€ ì „ë…„ ëŒ€ë¹„ 5% ì„±ì¥í•œ 6,500ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì „ ì„¸ê³„ì ìœ¼ë¡œ ëŒ€ë§ˆì´ˆ ì‚°ì—…ì€ ê³„ì† ë°œì „í•˜ê³  ìˆìœ¼ë©°, TilrayëŠ” ì „ ì„¸ê³„ ì–´ë–¤ ìƒì—…ì  ì‹œì¥ì—ì„œë„ ê²½ìŸí•˜ê³  ì„ ë„í•  ìˆ˜ ìˆëŠ” ì ì •í•œ ë¹„ìš©ì˜ ì¬ë°° ë° ì œì¡° ë¯¼ì²©ì„±ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìµœê·¼ ë¯¸êµ­ ë‚´ ë™í–¥ì€ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆì˜ ì¬ë¶„ë¥˜ì— ëŒ€í•œ ë‹¹ì‚¬ì˜ ë‚™ê´€ë¡ ì„ ë”ìš± ê°•í™”ì‹œì¼°ìœ¼ë©°, ì´ëŠ” ì „ ì„¸ê³„ ë‹¤ë¥¸ êµ­ê°€ë“¤ì—ì„œë„ ëª©ê²©í•œ ë°”ì™€ ê°™ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì¬ë¶„ë¥˜ê°€ í™˜ì ì ‘ê·¼ì„±ì„ í–¥ìƒì‹œí‚¤ê³  í™˜ì ì¹˜ë£Œì˜ ì§ˆì„ ê°œì„ í•˜ë©°, ê³¼í•™ì  ì—°êµ¬ë¥¼ ì´‰ì§„í•˜ê³  ì±…ì„ê° ìˆëŠ” ê·œì œ í”„ë ˆì„ì›Œí¬ë¥¼ ì§€ì›í•  ê²ƒì´ë¼ê³  ë¯¿ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The medical cannabis industry in the U.S. currently estimated to be at least a $10 billion market, which would create a potential opportunity for Tilray to capture at least a 3% to 5% market share, representing a significant $300 million to $500 million business opportunity. We've identified multiple pathways to participate in the U.S. medical cannabis industry, positioning ourselves to take advantage of the substantial growth potential when it happens. In Q1, our Canadian cannabis business delivered strong results. Tilray reinforced its position as Canada's largest legal cannabis company by revenue with Q1 revenue up 4% year-over-year to $51 million.</td><td>ë¯¸êµ­ì˜ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆ ì‚°ì—…ì€ í˜„ì¬ ìµœì†Œ 100ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì‹œì¥ìœ¼ë¡œ ì¶”ì •ë˜ë©°, ì´ëŠ” Tilrayê°€ ìµœì†Œ 3%ì—ì„œ 5%ì˜ ì‹œì¥ì ìœ ìœ¨ì„ í™•ë³´í•  ìˆ˜ ìˆëŠ” ì ì¬ì  ê¸°íšŒë¥¼ ì°½ì¶œí•˜ì—¬ 3ì–µ ë‹¬ëŸ¬ì—ì„œ 5ì–µ ë‹¬ëŸ¬ì— ì´ë¥´ëŠ” ìƒë‹¹í•œ ì‚¬ì—… ê¸°íšŒë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤. ì €í¬ëŠ” ë¯¸êµ­ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆ ì‚°ì—…ì— ì°¸ì—¬í•  ìˆ˜ ìˆëŠ” ë‹¤ì–‘í•œ ê²½ë¡œë¥¼ íŒŒì•…í–ˆìœ¼ë©°, ê¸°íšŒê°€ ì™”ì„ ë•Œ ìƒë‹¹í•œ ì„±ì¥ ì ì¬ë ¥ì„ í™œìš©í•  ìˆ˜ ìˆë„ë¡ í¬ì§€ì…”ë‹í•˜ê³  ìˆìŠµë‹ˆë‹¤. 1ë¶„ê¸°ì— ì €í¬ ìºë‚˜ë‹¤ ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì€ ê°•ë ¥í•œ ì‹¤ì ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. TilrayëŠ” 1ë¶„ê¸° ë§¤ì¶œì´ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 4% ì¦ê°€í•œ 5,100ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ë©° ë§¤ì¶œ ê¸°ì¤€ ìºë‚˜ë‹¤ ìµœëŒ€ í•©ë²• ëŒ€ë§ˆì´ˆ íšŒì‚¬ë¡œì„œì˜ ì§€ìœ„ë¥¼ í™•ê³ íˆ í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In the adult-use channel, Tilray was the top 5 licensed producer. We grew in market share, closing the gap to the #1 LP in market share by 53 basis points. We held the #1 position in key categories such as pre-rolls, beverages, oils, chocolate edibles. And by the end of the quarter, we also reached the #1 spot in flower while maintaining our top 10 positions across all categories. Congratulations to Blair and his team.</td><td>ì„±ì¸ìš© ì±„ë„ì—ì„œ TilrayëŠ” ìƒìœ„ 5ìœ„ ë¼ì´ì„ ìŠ¤ ìƒì‚°ì—…ì²´ì˜€ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ì—¬ 1ìœ„ LPì™€ì˜ ì‹œì¥ ì ìœ ìœ¨ ê²©ì°¨ë¥¼ 53ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸ ì¤„ì˜€ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” í”„ë¦¬ë¡¤, ìŒë£Œ, ì˜¤ì¼, ì´ˆì½œë¦¿ ì—ë””ë¸” ë“± ì£¼ìš” ì¹´í…Œê³ ë¦¬ì—ì„œ 1ìœ„ ìë¦¬ë¥¼ ìœ ì§€í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¶„ê¸° ë§ê¹Œì§€ ëª¨ë“  ì¹´í…Œê³ ë¦¬ì—ì„œ ìƒìœ„ 10ìœ„ ë‚´ í¬ì§€ì…˜ì„ ìœ ì§€í•˜ë©´ì„œ í”Œë¼ì›Œ ë¶€ë¬¸ì—ì„œë„ 1ìœ„ì— ë„ë‹¬í–ˆìŠµë‹ˆë‹¤. Blairì™€ ê·¸ì˜ íŒ€ì—ê²Œ ì¶•í•˜ë¥¼ ì „í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We believe our extensive scale represents a significant competitive advantage within the Canadian market, where we manage approximately 5 million square feet of cultivation space and currently maintain 210 metric tons of cannabis in production with additional capacity readily available. This position us to effectively meet future demand. Furthermore, Tilray is well prepared to supply both European and U.S. markets as regulatory framework develops these markets and it continues to expand.</td><td>ì €í¬ëŠ” ê´‘ë²”ìœ„í•œ ê·œëª¨ê°€ ìºë‚˜ë‹¤ ì‹œì¥ ë‚´ì—ì„œ ìƒë‹¹í•œ ê²½ìŸ ìš°ìœ„ë¥¼ ë‚˜íƒ€ë‚¸ë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì•½ 500ë§Œ í‰ë°©í”¼íŠ¸ì˜ ì¬ë°° ê³µê°„ì„ ê´€ë¦¬í•˜ê³  ìˆìœ¼ë©°, í˜„ì¬ 210ë¯¸í„°í†¤ì˜ ëŒ€ë§ˆì´ˆë¥¼ ìƒì‚° ì¤‘ì´ê³  ì¶”ê°€ ìƒì‚°ëŠ¥ë ¥ë„ ì¦‰ì‹œ í™œìš© ê°€ëŠ¥í•œ ìƒíƒœì…ë‹ˆë‹¤. ì´ëŠ” ì €í¬ê°€ ë¯¸ë˜ ìˆ˜ìš”ë¥¼ íš¨ê³¼ì ìœ¼ë¡œ ì¶©ì¡±í•  ìˆ˜ ìˆëŠ” ìœ„ì¹˜ì— ìˆìŒì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ë˜í•œ TilrayëŠ” ê·œì œ í”„ë ˆì„ì›Œí¬ê°€ ë°œì „í•˜ê³  ì‹œì¥ì´ ì§€ì†ì ìœ¼ë¡œ í™•ì¥ë¨ì— ë”°ë¼ ìœ ëŸ½ê³¼ ë¯¸êµ­ ì‹œì¥ ëª¨ë‘ì— ê³µê¸‰í•  ì¤€ë¹„ê°€ ì˜ ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Canada, we also foresee substantial potential as regulatory reforms may lead to transformative developments such as expanding cannabis in health care, unlocking new opportunities through proposed cannabis health products and broader insurance coverage, making medical cannabis more accessible to patients. On-premise consumption for THC beverages, which I believe is big, a rollout of on-site consumption to drive responsible use and create a vibrant experimental cannabis beverage market.</td><td>ìºë‚˜ë‹¤ì—ì„œë„ ê·œì œ ê°œí˜ì´ í—¬ìŠ¤ì¼€ì–´ ë¶„ì•¼ì—ì„œì˜ ëŒ€ë§ˆì´ˆ í™•ëŒ€, ì œì•ˆëœ ëŒ€ë§ˆì´ˆ ê±´ê°• ì œí’ˆì„ í†µí•œ ìƒˆë¡œìš´ ê¸°íšŒ ì°½ì¶œ, ê·¸ë¦¬ê³  ë” ê´‘ë²”ìœ„í•œ ë³´í—˜ ì ìš©ì„ í†µí•´ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆë¥¼ í™˜ìë“¤ì´ ë” ì‰½ê²Œ ì ‘ê·¼í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ë“± í˜ì‹ ì ì¸ ë°œì „ìœ¼ë¡œ ì´ì–´ì§ˆ ìˆ˜ ìˆì–´ ìƒë‹¹í•œ ì ì¬ë ¥ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì œê°€ ë³´ê¸°ì— í° ì˜ë¯¸ê°€ ìˆëŠ” THC ìŒë£Œì˜ í˜„ì¥ ì†Œë¹„, ì¦‰ í˜„ì¥ ì†Œë¹„ì˜ í™•ì‚°ì„ í†µí•´ ì±…ì„ê° ìˆëŠ” ì‚¬ìš©ì„ ì´‰ì§„í•˜ê³  í™œê¸°ì°¬ ì‹¤í—˜ì  ëŒ€ë§ˆì´ˆ ìŒë£Œ ì‹œì¥ì„ ì°½ì¶œí•˜ëŠ” ê²ƒë„ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>And of course, regulatory modernization, which we've been talking about, updating the outdated policies that restrict competitiveness and paving the way for innovation and growth in Canadian cannabis industry. Turning to our International business. Our international cannabis revenue grew 10% year-over-year to $13.4 million. And this is with not being able to obtain permits in Portugal to allow us to ship around the rest of the countries. And we remain uniquely positioned to gain market share as the global consumer preferences and the regulations evolve.</td><td>ë¬¼ë¡  ìš°ë¦¬ê°€ ê³„ì† ë…¼ì˜í•´ì˜¨ ê·œì œ í˜„ëŒ€í™”ë„ ìˆìŠµë‹ˆë‹¤. ê²½ìŸë ¥ì„ ì œí•œí•˜ëŠ” êµ¬ì‹ ì •ì±…ë“¤ì„ ì—…ë°ì´íŠ¸í•˜ê³  ìºë‚˜ë‹¤ ëŒ€ë§ˆì´ˆ ì‚°ì—…ì˜ í˜ì‹ ê³¼ ì„±ì¥ì„ ìœ„í•œ ê¸¸ì„ ì—´ì–´ê°€ëŠ” ê²ƒì…ë‹ˆë‹¤. <br><br>êµ­ì œ ì‚¬ì—…ìœ¼ë¡œ ë„˜ì–´ê°€ë©´, êµ­ì œ ëŒ€ë§ˆì´ˆ ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 10% ì¦ê°€í•œ 1,340ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” í¬ë¥´íˆ¬ê°ˆì—ì„œ ë‹¤ë¥¸ êµ­ê°€ë“¤ë¡œ ì œí’ˆì„ ì¶œí•˜í•  ìˆ˜ ìˆëŠ” í—ˆê°€ë¥¼ ë°›ì§€ ëª»í•œ ìƒí™©ì—ì„œ ë‹¬ì„±í•œ ì„±ê³¼ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ê¸€ë¡œë²Œ ì†Œë¹„ì ì„ í˜¸ë„ì™€ ê·œì œê°€ ë³€í™”í•¨ì— ë”°ë¼ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•  ìˆ˜ ìˆëŠ” ë…íŠ¹í•œ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Germany, we continue to expand our commercial medical cannabis portfolio and are actively leveraging our Tilray Medical and CC Pharma distribution network across pharmacies throughout the country to drive further growth. Looking ahead, we expect to increase our medical cannabis distribution footprint by threefold in fiscal 2026, significantly enhancing our reach and impact within the German pharmaceutical market, and we have that access through CC Pharma. In Italy, our Italian subsidiary, FL Group received the first license from the Italian Ministry of Health to distribute medical cannabis flower for therapeutic use.</td><td>ë…ì¼ì—ì„œëŠ” ìƒì—…ìš© ì˜ë£Œìš© ëŒ€ë§ˆì´ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì§€ì†ì ìœ¼ë¡œ í™•ì¥í•˜ê³  ìˆìœ¼ë©°, ì „êµ­ ì•½êµ­ì— ê±¸ì³ êµ¬ì¶•ëœ Tilray Medicalê³¼ CC Pharma ìœ í†µ ë„¤íŠ¸ì›Œí¬ë¥¼ ì ê·¹ í™œìš©í•˜ì—¬ ì¶”ê°€ ì„±ì¥ì„ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. í–¥í›„ ì „ë§ì„ ë³´ë©´, 2026 íšŒê³„ì—°ë„ì—ëŠ” ì˜ë£Œìš© ëŒ€ë§ˆì´ˆ ìœ í†µ ì˜ì—­ì„ 3ë°° í™•ëŒ€í•˜ì—¬ ë…ì¼ ì œì•½ ì‹œì¥ ë‚´ì—ì„œì˜ ë„ë‹¬ ë²”ìœ„ì™€ ì˜í–¥ë ¥ì„ í¬ê²Œ ê°•í™”í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” CC Pharmaë¥¼ í†µí•œ ì ‘ê·¼ì„± í™•ë³´ë¡œ ê°€ëŠ¥í•©ë‹ˆë‹¤. ì´íƒˆë¦¬ì•„ì—ì„œëŠ” ë‹¹ì‚¬ì˜ ì´íƒˆë¦¬ì•„ ìíšŒì‚¬ì¸ FL Groupì´ ì¹˜ë£Œ ëª©ì ì˜ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆ ê½ƒì„ ìœ í†µí•  ìˆ˜ ìˆëŠ” ì²« ë²ˆì§¸ ë¼ì´ì„ ìŠ¤ë¥¼ ì´íƒˆë¦¬ì•„ ë³´ê±´ë¶€ë¡œë¶€í„° íšë“í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We also partner with Molteni, a leading Italian pharmaceutical company, to expand access to medical cannabis extracts and provide targeted education through their national network of medical and scientific professionals. We continue to expand our growing capabilities in both Portugal and Germany, strengthening our EU GMP certified cultivation infrastructure and to meet evolving global demand. Currently, we produce 21 metric tons of medical cannabis flower in Europe and have the capacity to significantly increase the amount as demand continues to grow.</td><td>ë˜í•œ ì €í¬ëŠ” ì´íƒˆë¦¬ì•„ì˜ ì„ ë„ì ì¸ ì œì•½íšŒì‚¬ì¸ ëª°í…Œë‹ˆ(Molteni)ì™€ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì˜ë£Œìš© ëŒ€ë§ˆ ì¶”ì¶œë¬¼ì— ëŒ€í•œ ì ‘ê·¼ì„±ì„ í™•ëŒ€í•˜ê³ , ëª°í…Œë‹ˆì˜ ì „êµ­ ì˜ë£Œì§„ ë° ê³¼í•™ ì „ë¬¸ê°€ ë„¤íŠ¸ì›Œí¬ë¥¼ í†µí•´ í‘œì í™”ëœ êµìœ¡ì„ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” í¬ë¥´íˆ¬ê°ˆê³¼ ë…ì¼ ëª¨ë‘ì—ì„œ ì¬ë°° ì—­ëŸ‰ì„ ì§€ì†ì ìœ¼ë¡œ í™•ì¥í•˜ì—¬ EU GMP ì¸ì¦ ì¬ë°° ì¸í”„ë¼ë¥¼ ê°•í™”í•˜ê³  ì§„í™”í•˜ëŠ” ê¸€ë¡œë²Œ ìˆ˜ìš”ì— ë¶€ì‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì €í¬ëŠ” ìœ ëŸ½ì—ì„œ 21ë¯¸í„°í†¤ì˜ ì˜ë£Œìš© ëŒ€ë§ˆ ê½ƒì„ ìƒì‚°í•˜ê³  ìˆìœ¼ë©°, ìˆ˜ìš”ê°€ ì§€ì†ì ìœ¼ë¡œ ì¦ê°€í•¨ì— ë”°ë¼ ìƒì‚°ëŸ‰ì„ í¬ê²Œ ëŠ˜ë¦´ ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our expanded growing operations not only supports our leadership in established markets, but also positions us to rapidly respond to the regulatory environments open across Europe and way beyond. European cannabis reform continues to progress, and we're seeing that. And we're excited to witness important developments like the European Union's [ CATAPULT ] project and Spain's recent approval of medical cannabis. Tilray is proud already to be involved in medical cannabis research in Spain through a partnership with the University of Madrid, supporting advancements in patient care and responsible regulations across Europe. Now on to our distribution.</td><td>ìš°ë¦¬ì˜ í™•ì¥ëœ ì¬ë°° ìš´ì˜ì€ ê¸°ì¡´ ì‹œì¥ì—ì„œì˜ ë¦¬ë”ì‹­ì„ ë’·ë°›ì¹¨í•  ë¿ë§Œ ì•„ë‹ˆë¼, ìœ ëŸ½ ì „ì—­ê³¼ ê·¸ ë„ˆë¨¸ì—ì„œ ì—´ë¦¬ëŠ” ê·œì œ í™˜ê²½ì— ì‹ ì†í•˜ê²Œ ëŒ€ì‘í•  ìˆ˜ ìˆëŠ” ìœ„ì¹˜ì— ìš°ë¦¬ë¥¼ ë†“ì•„ì¤ë‹ˆë‹¤. ìœ ëŸ½ì˜ ëŒ€ë§ˆì´ˆ ê°œí˜ì€ ê³„ì†í•´ì„œ ì§„ì „ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ìš°ë¦¬ëŠ” ì´ë¥¼ ëª©ê²©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ìœ ëŸ½ì—°í•©ì˜ [CATAPULT] í”„ë¡œì íŠ¸ì™€ ìŠ¤í˜ì¸ì˜ ìµœê·¼ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆ ìŠ¹ì¸ê³¼ ê°™ì€ ì¤‘ìš”í•œ ë°œì „ë“¤ì„ ì§€ì¼œë³´ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. TilrayëŠ” ì´ë¯¸ ë§ˆë“œë¦¬ë“œ ëŒ€í•™êµì™€ì˜ íŒŒíŠ¸ë„ˆì‹­ì„ í†µí•´ ìŠ¤í˜ì¸ì˜ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆ ì—°êµ¬ì— ì°¸ì—¬í•˜ê³  ìˆìŒì„ ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•˜ë©°, ì´ëŠ” ìœ ëŸ½ ì „ì—­ì˜ í™˜ì ì¹˜ë£Œ ë°œì „ê³¼ ì±…ì„ê° ìˆëŠ” ê·œì œë¥¼ ì§€ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ìš°ë¦¬ì˜ ìœ í†µì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our European medical distribution business, CC Pharma continues to grow with revenue increasing 9% year-over-year to $74 million. This segment remains a significant driver of our European cannabis operations and our infrastructure provides a strategic advantage that enable us to capture increased market share as both the regulatory environment and industry landscape evolves across Europe. And as I said before, we have access to over 13,000 drug stores within the German market. We remain confident in our global expansion strategy with Tilray well positioned to drive international growth and leveraging emerging opportunities across Cannabis, Beverage and our Wellness business.</td><td>ìœ ëŸ½ ì˜ë£Œ ìœ í†µ ì‚¬ì—…ì¸ CC PharmaëŠ” ì§€ì†ì ì¸ ì„±ì¥ì„ ë³´ì´ë©°, ë§¤ì¶œì´ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 9% ì¦ê°€í•œ 7,400ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¬¸ì€ ìœ ëŸ½ ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì˜ ì¤‘ìš”í•œ ì„±ì¥ ë™ë ¥ìœ¼ë¡œ ë‚¨ì•„ìˆìœ¼ë©°, ìœ ëŸ½ ì „ì—­ì—ì„œ ê·œì œ í™˜ê²½ê³¼ ì‚°ì—… í™˜ê²½ì´ ë³€í™”í•¨ì— ë”°ë¼ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ë¥¼ ê°€ëŠ¥í•˜ê²Œ í•˜ëŠ” ì „ëµì  ìš°ìœ„ë¥¼ ì œê³µí•˜ëŠ” ì¸í”„ë¼ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ë…ì¼ ì‹œì¥ ë‚´ 13,000ê°œ ì´ìƒì˜ ì•½êµ­ì— ì ‘ê·¼í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ëŒ€ë§ˆì´ˆ, ìŒë£Œ ë° ì›°ë‹ˆìŠ¤ ì‚¬ì—… ì „ë°˜ì— ê±¸ì³ ìƒˆë¡œìš´ ê¸°íšŒë¥¼ í™œìš©í•˜ê³  êµ­ì œì  ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆëŠ” Tilrayì™€ í•¨ê»˜ ê¸€ë¡œë²Œ í™•ì¥ ì „ëµì— ëŒ€í•œ í™•ì‹ ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>International beverage, which is a new business for us, building on our international footprint, our infrastructure, our growth strategy, we will be accelerating the expansion of our nonalcoholic beverages portfolio across multiple international markets. We expect our brands, HiBall, Liquid Love, Runner's High to gain traction with consumer opportunities. We built a dedicated team focused exclusively on servicing our international customers. This specialized team will ensure that our portfolio of leading craft brands is tailored to the taste and expectations of our global consumers while also supporting our long-term growth in high potential markets worldwide.</td><td>êµ­ì œ ìŒë£Œ ì‚¬ì—…ì€ ì €í¬ì—ê²Œ ìƒˆë¡œìš´ ì‚¬ì—… ì˜ì—­ìœ¼ë¡œ, ì €í¬ì˜ êµ­ì œì  ì…ì§€, ì¸í”„ë¼, ì„±ì¥ ì „ëµì„ ë°”íƒ•ìœ¼ë¡œ ì—¬ëŸ¬ êµ­ì œ ì‹œì¥ì—ì„œ ë¬´ì•Œì½”ì˜¬ ìŒë£Œ í¬íŠ¸í´ë¦¬ì˜¤ì˜ í™•ì¥ì„ ê°€ì†í™”í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì €í¬ ë¸Œëœë“œì¸ HiBall, Liquid Love, Runner's Highê°€ ì†Œë¹„ì ê¸°íšŒì™€ í•¨ê»˜ ê²¬ì¸ë ¥ì„ ì–»ì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ì €í¬ëŠ” êµ­ì œ ê³ ê° ì„œë¹„ìŠ¤ì—ë§Œ ì „ë‹´í•˜ëŠ” ì „ë¬¸ íŒ€ì„ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤. ì´ ì „ë¬¸ íŒ€ì€ ì €í¬ì˜ ì„ ë„ì ì¸ í¬ë˜í”„íŠ¸ ë¸Œëœë“œ í¬íŠ¸í´ë¦¬ì˜¤ê°€ ê¸€ë¡œë²Œ ì†Œë¹„ìë“¤ì˜ ì·¨í–¥ê³¼ ê¸°ëŒ€ì— ë§ì¶°ì§€ë„ë¡ í•˜ëŠ” ë™ì‹œì— ì „ ì„¸ê³„ ê³ ì„±ì¥ ì ì¬ë ¥ ì‹œì¥ì—ì„œì˜ ì¥ê¸°ì  ì„±ì¥ì„ ì§€ì›í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>By leveraging our established distribution networks and brand-building expertise, we are well positioned to capture growth opportunities in this fast emerging category and delivering exciting new products to the international markets, and the demand for them is high. Notably, we've already secured a distribution partner in the U.K. for HiBall, ensuring rapid market entry and strong support for the brand in this key region. Additionally, on the beer side, we recognize the growing demand for American craft beers in the international market.</td><td>ê¸°ì¡´ì˜ ìœ í†µ ë„¤íŠ¸ì›Œí¬ì™€ ë¸Œëœë“œ êµ¬ì¶• ì „ë¬¸ì„±ì„ í™œìš©í•˜ì—¬, ë‹¹ì‚¬ëŠ” ì´ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì¹´í…Œê³ ë¦¬ì—ì„œ ì„±ì¥ ê¸°íšŒë¥¼ í¬ì°©í•˜ê³  êµ­ì œ ì‹œì¥ì— í¥ë¯¸ì§„ì§„í•œ ì‹ ì œí’ˆì„ ì¶œì‹œí•  ìˆ˜ ìˆëŠ” ìœ ë¦¬í•œ ìœ„ì¹˜ì— ìˆìœ¼ë©°, ì´ì— ëŒ€í•œ ìˆ˜ìš”ëŠ” ë†’ìŠµë‹ˆë‹¤. íŠ¹íˆ ì£¼ëª©í•  ì ì€, ë‹¹ì‚¬ê°€ ì´ë¯¸ HiBallì˜ ì˜êµ­ ë‚´ ìœ í†µ íŒŒíŠ¸ë„ˆë¥¼ í™•ë³´í•˜ì—¬ ì´ í•µì‹¬ ì§€ì—­ì—ì„œ ì‹ ì†í•œ ì‹œì¥ ì§„ì…ê³¼ ë¸Œëœë“œì— ëŒ€í•œ ê°•ë ¥í•œ ì§€ì›ì„ ë³´ì¥í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ë§¥ì£¼ ë¶€ë¬¸ì—ì„œëŠ” êµ­ì œ ì‹œì¥ì—ì„œ ë¯¸êµ­ í¬ë˜í”„íŠ¸ ë§¥ì£¼ì— ëŒ€í•œ ìˆ˜ìš”ê°€ ì¦ê°€í•˜ê³  ìˆìŒì„ ì¸ì‹í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>To further capitalize on this momentum, we're actively exploring all opportunities to grow this business, including international manufacturing opportunities, potential acquisitions to expand our reach and better serve our global customers. In our U.S. Beverage business, we continue to make progress against our beer integration, optimizing our strategy and our Project 420. We see long-term potential for the beverage category based on the diversification of our offerings and the superior products we produce. We've improved operations, leveraged acquired brands, supporting positive performance.</td><td>ì´ëŸ¬í•œ ëª¨ë©˜í…€ì„ ë”ìš± í™œìš©í•˜ê¸° ìœ„í•´, ì €í¬ëŠ” êµ­ì œ ì œì¡° ê¸°íšŒ, ê¸€ë¡œë²Œ ê³ ê°ë“¤ì—ê²Œ ë” ë‚˜ì€ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ê³  ì‚¬ì—… ì˜ì—­ì„ í™•ì¥í•˜ê¸° ìœ„í•œ ì ì¬ì  ì¸ìˆ˜ ë“±ì„ í¬í•¨í•˜ì—¬ ì´ ì‚¬ì—…ì„ ì„±ì¥ì‹œí‚¬ ìˆ˜ ìˆëŠ” ëª¨ë“  ê¸°íšŒë¥¼ ì ê·¹ì ìœ¼ë¡œ ëª¨ìƒ‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ìŒë£Œ ì‚¬ì—…ì—ì„œëŠ” ë§¥ì£¼ í†µí•©, ì „ëµ ìµœì í™” ë° í”„ë¡œì íŠ¸ 420ì— ëŒ€í•´ ì§€ì†ì ìœ¼ë¡œ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë‹¤ì–‘í•œ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì™€ ìš°ìˆ˜í•œ ì œí’ˆ ìƒì‚°ì„ ë°”íƒ•ìœ¼ë¡œ ìŒë£Œ ì¹´í…Œê³ ë¦¬ì˜ ì¥ê¸°ì  ì ì¬ë ¥ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ìš´ì˜ì„ ê°œì„ í•˜ê³  ì¸ìˆ˜í•œ ë¸Œëœë“œë“¤ì„ í™œìš©í•˜ì—¬ ê¸ì •ì ì¸ ì„±ê³¼ë¥¼ ë’·ë°›ì¹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Notably, many of these brands Tilray acquired were previously in decline and are now showing promising results with healthier growth trends and improved overall performance as we move to regain sales authorizations at retail that were lost. This turnaround underscores the success of our focused strategy and our commitment to revitalizing and growing our beverage beer portfolio. Through Project 420, we've realized $25 million in annual savings, moving closer to our goal of $33 million. We continue to work closely with our distributors to concentrate on promoting strong brands in each of our markets. In the quarter, we experienced growth across key brands and regions.</td><td>íŠ¹íˆ Tilrayê°€ ì¸ìˆ˜í•œ ì´ëŸ¬í•œ ë¸Œëœë“œë“¤ ì¤‘ ë‹¤ìˆ˜ëŠ” ì´ì „ì— í•˜ë½ì„¸ë¥¼ ë³´ì´ê³  ìˆì—ˆìœ¼ë‚˜, í˜„ì¬ëŠ” ë”ìš± ê±´ì „í•œ ì„±ì¥ ì¶”ì„¸ì™€ ì „ë°˜ì ì¸ ì„±ê³¼ ê°œì„ ì„ í†µí•´ ìœ ë§í•œ ê²°ê³¼ë¥¼ ë³´ì—¬ì£¼ê³  ìˆìœ¼ë©°, ìƒì—ˆë˜ ì†Œë§¤ íŒë§¤ ìŠ¹ì¸ì„ ë˜ì°¾ì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í„´ì–´ë¼ìš´ë“œëŠ” ìš°ë¦¬ì˜ ì§‘ì¤‘ì ì¸ ì „ëµì˜ ì„±ê³µê³¼ ìŒë£Œ ë§¥ì£¼ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í™œì„±í™”í•˜ê³  ì„±ì¥ì‹œí‚¤ë ¤ëŠ” ìš°ë¦¬ì˜ ì˜ì§€ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. í”„ë¡œì íŠ¸ 420ì„ í†µí•´ ìš°ë¦¬ëŠ” ì—°ê°„ 2,500ë§Œ ë‹¬ëŸ¬ì˜ ë¹„ìš© ì ˆê°ì„ ì‹¤í˜„í–ˆìœ¼ë©°, 3,300ë§Œ ë‹¬ëŸ¬ë¼ëŠ” ëª©í‘œì— ë”ìš± ê°€ê¹Œì›Œì§€ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê° ì‹œì¥ì—ì„œ ê°•ë ¥í•œ ë¸Œëœë“œ í™ë³´ì— ì§‘ì¤‘í•˜ê¸° ìœ„í•´ ìœ í†µì—…ì²´ë“¤ê³¼ ì§€ì†ì ìœ¼ë¡œ ê¸´ë°€íˆ í˜‘ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì—ëŠ” ì£¼ìš” ë¸Œëœë“œì™€ ì§€ì—­ ì „ë°˜ì—ì„œ ì„±ì¥ì„ ê²½í—˜í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Shock Top, the company's third largest brand, was among the fastest-growing craft brand with notable increase in both dollar sales and market share, driven in part by the successful launch of its [ Ryde ] pack, which has grown to be the #8 most popular new craft beer nationally. Trends continue to improve for Shock Top with a 30-point dollar trend improvement since Tilray acquired the brand in 2023. In the Southeast, Shock Top excelled with a 49% jump in dollar sales. SweetWater Daytrip IPA stood out as one of the top new items in the region.</td><td>íšŒì‚¬ì˜ 3ë²ˆì§¸ ëŒ€í˜• ë¸Œëœë“œì¸ Shock Topì€ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” í¬ë˜í”„íŠ¸ ë¸Œëœë“œ ì¤‘ í•˜ë‚˜ë¡œ, ë‹¬ëŸ¬ ë§¤ì¶œê³¼ ì‹œì¥ ì ìœ ìœ¨ ëª¨ë‘ì—ì„œ ì£¼ëª©í•  ë§Œí•œ ì¦ê°€ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ëŠ” ë¶€ë¶„ì ìœ¼ë¡œ [Ryde] íŒ©ì˜ ì„±ê³µì ì¸ ì¶œì‹œì— í˜ì…ì€ ê²ƒìœ¼ë¡œ, ì´ ì œí’ˆì€ ì „êµ­ì ìœ¼ë¡œ 8ë²ˆì§¸ë¡œ ì¸ê¸° ìˆëŠ” ì‹ ê·œ í¬ë˜í”„íŠ¸ ë§¥ì£¼ë¡œ ì„±ì¥í–ˆìŠµë‹ˆë‹¤. Shock Topì˜ íŠ¸ë Œë“œëŠ” Tilrayê°€ 2023ë…„ ì´ ë¸Œëœë“œë¥¼ ì¸ìˆ˜í•œ ì´í›„ ë‹¬ëŸ¬ íŠ¸ë Œë“œê°€ 30í¬ì¸íŠ¸ ê°œì„ ë˜ëŠ” ë“± ì§€ì†ì ìœ¼ë¡œ í–¥ìƒë˜ê³  ìˆìŠµë‹ˆë‹¤. ë‚¨ë™ë¶€ ì§€ì—­ì—ì„œ Shock Topì€ ë‹¬ëŸ¬ ë§¤ì¶œì´ 49% ê¸‰ì¦í•˜ë©° ë›°ì–´ë‚œ ì„±ê³¼ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. SweetWater Daytrip IPAëŠ” í•´ë‹¹ ì§€ì—­ì—ì„œ ìµœê³ ì˜ ì‹ ì œí’ˆ ì¤‘ í•˜ë‚˜ë¡œ ë‘ê°ì„ ë‚˜íƒ€ëƒˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Northeast, Montauk maintained its leading position in Metro New York and gained market share nationally with continued demand for its Wave Chaser IPA. Breckenridge Brewery led craft share gains in Colorado with its top Avalanche seasonal and Juice Drop and brands positioning double-digit growth. And last but not least, Redhook outperformed regional craft beer brands propelled by Big Ballard Imperial IPA strong volumes and our velocity gains, while 10-barrel pub beer 18-packs dominated craft sales in Oregon and 5% of all craft volumes.</td><td>ë™ë¶ë¶€ ì§€ì—­ì—ì„œ Montaukì€ ë‰´ìš• ë©”íŠ¸ë¡œ ì§€ì—­ì—ì„œ ì„ ë„ì  ì§€ìœ„ë¥¼ ìœ ì§€í–ˆìœ¼ë©°, Wave Chaser IPAì— ëŒ€í•œ ì§€ì†ì ì¸ ìˆ˜ìš”ë¡œ ì „êµ­ì ìœ¼ë¡œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. Breckenridge BreweryëŠ” ìµœê³  ì¸ê¸° ì‹œì¦Œ ë§¥ì£¼ì¸ Avalancheì™€ Juice Drop ë¸Œëœë“œë“¤ì´ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í•˜ë©° ì½œë¡œë¼ë„ì—ì„œ í¬ë˜í”„íŠ¸ ë§¥ì£¼ ì ìœ ìœ¨ ì¦ê°€ë¥¼ ì£¼ë„í–ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ Redhookì€ Big Ballard Imperial IPAì˜ ê°•ë ¥í•œ íŒë§¤ëŸ‰ê³¼ ì†ë„ ì¦ê°€ì— í˜ì…ì–´ ì§€ì—­ í¬ë˜í”„íŠ¸ ë§¥ì£¼ ë¸Œëœë“œë“¤ì„ ëŠ¥ê°€í•˜ëŠ” ì„±ê³¼ë¥¼ ë³´ì˜€ìœ¼ë©°, 10-barrel pub beer 18íŒ©ì€ ì˜¤ë¦¬ê±´ì£¼ í¬ë˜í”„íŠ¸ ë§¥ì£¼ íŒë§¤ë¥¼ ì¥ì•…í•˜ì—¬ ì „ì²´ í¬ë˜í”„íŠ¸ ë§¥ì£¼ íŒë§¤ëŸ‰ì˜ 5%ë¥¼ ì°¨ì§€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We also expanded our partnerships, including co-brand craft beer with the Oregon Ducks, perfect for college football season and a new partnership with [indiscernible] for the launch of Shock Top Twisted Pretzel Wheat beer. You got to try it. It's great. We are making beer fun again, and these partnerships and co-branding opportunities offer significant runway for us to widen our markets. In spirits category, which has been tough. We have introduced several world-class innovation, including Mock One, our new line of nonalcohol spirits and Casa Breck in the tequila space.</td><td>ë˜í•œ ì˜¤ë¦¬ê±´ ë•ìŠ¤(Oregon Ducks)ì™€ì˜ ê³µë™ ë¸Œëœë“œ í¬ë˜í”„íŠ¸ ë§¥ì£¼ë¥¼ í¬í•¨í•œ íŒŒíŠ¸ë„ˆì‹­ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ëŒ€í•™ ë¯¸ì‹ì¶•êµ¬ ì‹œì¦Œì— ì™„ë²½í•œ ì œí’ˆì´ë©°, Shock Top Twisted Pretzel Wheat ë§¥ì£¼ ì¶œì‹œë¥¼ ìœ„í•œ [ì‹ë³„ë¶ˆê°€]ì™€ì˜ ìƒˆë¡œìš´ íŒŒíŠ¸ë„ˆì‹­ë„ ì²´ê²°í–ˆìŠµë‹ˆë‹¤. ê¼­ í•œë²ˆ ë“œì…”ë³´ì„¸ìš”. ì •ë§ í›Œë¥­í•©ë‹ˆë‹¤. ì €í¬ëŠ” ë§¥ì£¼ë¥¼ ë‹¤ì‹œ ì¬ë¯¸ìˆê²Œ ë§Œë“¤ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ íŒŒíŠ¸ë„ˆì‹­ê³¼ ê³µë™ ë¸Œëœë”© ê¸°íšŒëŠ” ì‹œì¥ì„ í™•ì¥í•  ìˆ˜ ìˆëŠ” ìƒë‹¹í•œ ì„±ì¥ ì—¬ë ¥ì„ ì œê³µí•©ë‹ˆë‹¤. ì–´ë ¤ì›€ì„ ê²ªê³  ìˆëŠ” ì£¼ë¥˜ ì¹´í…Œê³ ë¦¬ì—ì„œëŠ” ë¬´ì•Œì½”ì˜¬ ì£¼ë¥˜ì˜ ìƒˆë¡œìš´ ë¼ì¸ì¸ Mock Oneê³¼ ë°í‚¬ë¼ ë¶„ì•¼ì˜ Casa Breckì„ í¬í•¨í•˜ì—¬ ì—¬ëŸ¬ ì„¸ê³„ì  ìˆ˜ì¤€ì˜ í˜ì‹  ì œí’ˆì„ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We've also introduced Mountain Shot, a unique beverage blend, which may take mushrooms available in pouches, which is a unique packaging format to enhance the shot experience and capture the free spirit essence of the Rocky Mountains just in time for ski season. We also kicked off our fifth year partnership with the Denver Broncos with a new line of spirits, including limited editions, Broncos Honey Whiskey and Broncos Orange Creamscle ready-to-drink cocktail.</td><td>ì €í¬ëŠ” ë˜í•œ ë§ˆìš´í‹´ ìƒ·(Mountain Shot)ì´ë¼ëŠ” ë…íŠ¹í•œ ìŒë£Œ ë¸”ë Œë“œë¥¼ ì¶œì‹œí–ˆìŠµë‹ˆë‹¤. ì´ ì œí’ˆì€ íŒŒìš°ì¹˜ í˜•íƒœì˜ ë…íŠ¹í•œ í¬ì¥ ë°©ì‹ìœ¼ë¡œ ì œê³µë˜ëŠ” ë²„ì„¯ì„ í™œìš©í•  ìˆ˜ ìˆìœ¼ë©°, ì´ëŠ” ìƒ· ê²½í—˜ì„ í–¥ìƒì‹œí‚¤ê³  ìŠ¤í‚¤ ì‹œì¦Œì— ë§ì¶° ë¡œí‚¤ì‚°ë§¥ì˜ ììœ ë¡œìš´ ì •ì‹ ì„ ë‹´ì•„ë‚´ëŠ” ë…íŠ¹í•œ í¬ì¥ í˜•íƒœì…ë‹ˆë‹¤. ë˜í•œ ë´ë²„ ë¸Œë¡±ì½”ìŠ¤ì™€ì˜ 5ë…„ì°¨ íŒŒíŠ¸ë„ˆì‹­ì„ ìƒˆë¡œìš´ ì£¼ë¥˜ ë¼ì¸ìœ¼ë¡œ ì‹œì‘í–ˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” í•œì •íŒ ë¸Œë¡±ì½”ìŠ¤ í—ˆë‹ˆ ìœ„ìŠ¤í‚¤ì™€ ë¸Œë¡±ì½”ìŠ¤ ì˜¤ë Œì§€ í¬ë¦¼ì‹œí´ ì¦‰ì„ ì¹µí…Œì¼ì´ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>In the non-alc category, we're proud that our non-alc beer brand, Runner's High, which we only launched in fiscal 2025 is now recognized as one of the top 15 brands in non-alc beer and ranks the fourth fastest-growing non-alc beer in a hot category in the Southeast, selling across 4,500 distribution points. Following the success of our hemp-derived Delta-9 THC beverages, we've expanded Fizzy Jane and Happy Flower product lines to include 10-milligram formats, complementing the existing 5-milligram offerings and the consumers want these products.</td><td>ë¬´ì•Œì½”ì˜¬ ì¹´í…Œê³ ë¦¬ì—ì„œëŠ” 2025 íšŒê³„ì—°ë„ì— ì¶œì‹œí•œ ë¬´ì•Œì½”ì˜¬ ë§¥ì£¼ ë¸Œëœë“œì¸ Runner's Highê°€ ë¬´ì•Œì½”ì˜¬ ë§¥ì£¼ ë¶€ë¬¸ ìƒìœ„ 15ê°œ ë¸Œëœë“œ ì¤‘ í•˜ë‚˜ë¡œ ì¸ì •ë°›ì•˜ìœ¼ë©°, ë™ë‚¨ë¶€ ì§€ì—­ì˜ í•«í•œ ì¹´í…Œê³ ë¦¬ì—ì„œ ë„¤ ë²ˆì§¸ë¡œ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ë¬´ì•Œì½”ì˜¬ ë§¥ì£¼ë¡œ ìë¦¬ë§¤ê¹€í•˜ì—¬ 4,500ê°œ ìœ í†µì ì—ì„œ íŒë§¤ë˜ê³  ìˆë‹¤ëŠ” ì ì„ ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ëŒ€ë§ˆ ìœ ë˜ ë¸íƒ€-9 THC ìŒë£Œì˜ ì„±ê³µì— ì´ì–´, ê¸°ì¡´ 5ë°€ë¦¬ê·¸ë¨ ì œí’ˆê³¼ í•¨ê»˜ 10ë°€ë¦¬ê·¸ë¨ í¬ë§·ì„ í¬í•¨í•˜ë„ë¡ Fizzy Janeê³¼ Happy Flower ì œí’ˆ ë¼ì¸ì„ í™•ì¥í–ˆìœ¼ë©°, ì†Œë¹„ìë“¤ì´ ì´ëŸ¬í•œ ì œí’ˆë“¤ì„ ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The innovative [ HD9 ] category, leveraging our craft beer infrastructure and distribution networks, enabling us to deliver high-quality products to consumers across 14 states, whether they're new to the category or seeking enhanced experience. We have established partnership with retailers nationwide for HDD9 brands and now offer distribution to prominent wine, liquor outlets such as Total Wine & More, ABC Fine Wine & Spirits. In addition, in Q1, we saw further growth in regional grocery channels, including ShopRite, Stew Leonard's and Winn-Dixie. We continue on building on this positive trajectory as we move into Q2 and the rest of the year.</td><td>í˜ì‹ ì ì¸ [HD9] ì¹´í…Œê³ ë¦¬ëŠ” ë‹¹ì‚¬ì˜ í¬ë˜í”„íŠ¸ ë§¥ì£¼ ì¸í”„ë¼ì™€ ìœ í†µ ë„¤íŠ¸ì›Œí¬ë¥¼ í™œìš©í•˜ì—¬ 14ê°œ ì£¼ì— ê±¸ì³ ì†Œë¹„ìë“¤ì—ê²Œ ê³ í’ˆì§ˆ ì œí’ˆì„ ì œê³µí•  ìˆ˜ ìˆê²Œ í•´ì¤ë‹ˆë‹¤. ì´ëŠ” í•´ë‹¹ ì¹´í…Œê³ ë¦¬ë¥¼ ì²˜ìŒ ì ‘í•˜ëŠ” ì†Œë¹„ìë“  í–¥ìƒëœ ê²½í—˜ì„ ì¶”êµ¬í•˜ëŠ” ì†Œë¹„ìë“  ê´€ê³„ì—†ì´ ê°€ëŠ¥í•©ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” HDD9 ë¸Œëœë“œë¥¼ ìœ„í•´ ì „êµ­ ì†Œë§¤ì—…ì²´ë“¤ê³¼ íŒŒíŠ¸ë„ˆì‹­ì„ êµ¬ì¶•í–ˆìœ¼ë©°, í˜„ì¬ Total Wine & More, ABC Fine Wine & Spiritsì™€ ê°™ì€ ì£¼ìš” ì™€ì¸ ë° ì£¼ë¥˜ ë§¤ì¥ì— ìœ í†µì„ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ 1ë¶„ê¸°ì—ëŠ” ShopRite, Stew Leonard's, Winn-Dixieë¥¼ í¬í•¨í•œ ì§€ì—­ ì‹ë£Œí’ˆ ì±„ë„ì—ì„œ ì¶”ê°€ì ì¸ ì„±ì¥ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” 2ë¶„ê¸°ì™€ ì˜¬í•´ ë‚¨ì€ ê¸°ê°„ ë™ì•ˆ ì´ëŸ¬í•œ ê¸ì •ì ì¸ ê¶¤ë„ë¥¼ ì§€ì†ì ìœ¼ë¡œ êµ¬ì¶•í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Today, our Beverage business operates more than 20 brands, including 15 American craft beer brands across 7 network manufacturing facilities and 16 brewpubs. We're well diversified across craft beer, spirits, non-alc and now HD9 and energy drinks, we know that there is plenty of opportunity for growth in the beverage category. We have the right leadership, and we're pursuing the right growth strategy, and I'm tremendously excited about the future and the opportunities in the large beverage category. Last but not least, now turning to our Wellness business, which is near and dear to my heart. Our Wellness business had a strong quarter, growing revenues to over $15 million.</td><td>ì˜¤ëŠ˜ ì €í¬ ìŒë£Œ ì‚¬ì—…ë¶€ëŠ” 7ê°œì˜ ë„¤íŠ¸ì›Œí¬ ì œì¡° ì‹œì„¤ê³¼ 16ê°œì˜ ë¸Œë£¨íì„ í†µí•´ 15ê°œì˜ ë¯¸êµ­ í¬ë˜í”„íŠ¸ ë§¥ì£¼ ë¸Œëœë“œë¥¼ í¬í•¨í•˜ì—¬ 20ê°œ ì´ìƒì˜ ë¸Œëœë“œë¥¼ ìš´ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” í¬ë˜í”„íŠ¸ ë§¥ì£¼, ì£¼ë¥˜, ë¬´ì•Œì½”ì˜¬ ìŒë£Œ, ê·¸ë¦¬ê³  ì´ì œ HD9ì™€ ì—ë„ˆì§€ ë“œë§í¬ê¹Œì§€ ì˜ ë‹¤ê°í™”ë˜ì–´ ìˆìœ¼ë©°, ìŒë£Œ ì¹´í…Œê³ ë¦¬ì—ì„œ ì„±ì¥í•  ìˆ˜ ìˆëŠ” ì¶©ë¶„í•œ ê¸°íšŒê°€ ìˆë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì˜¬ë°”ë¥¸ ë¦¬ë”ì‹­ì„ ê°–ì¶”ê³  ìˆê³ , ì˜¬ë°”ë¥¸ ì„±ì¥ ì „ëµì„ ì¶”ì§„í•˜ê³  ìˆìœ¼ë©°, ëŒ€ê·œëª¨ ìŒë£Œ ì¹´í…Œê³ ë¦¬ì˜ ë¯¸ë˜ì™€ ê¸°íšŒì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë§ˆì§€ë§‰ìœ¼ë¡œ, ì œ ë§ˆìŒì— ë§¤ìš° ì†Œì¤‘í•œ ì›°ë‹ˆìŠ¤ ì‚¬ì—…ë¶€ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì €í¬ ì›°ë‹ˆìŠ¤ ì‚¬ì—…ë¶€ëŠ” ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì ì„ ë³´ì˜€ìœ¼ë©°, ë§¤ì¶œì´ 1,500ë§Œ ë‹¬ëŸ¬ë¥¼ ë„˜ì–´ì„œë©° ì„±ì¥í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We continue to expand our Wellness portfolio with many launches of new offerings, new crackers, new hemp portfolio, new other products that are available at Whole Foods and other retailers. We are now in over 17,000 retailers across the U.S. These offerings are also launched in Amazon and many other online retailers. I'm highly confident in Tilray's outlook for the remainder of 2026 and beyond with regulatory environments in our industry poised for meaningful evolution. I fully expect positive change ahead, and I'm certain in our ability to adapt swiftly and we will strategically.</td><td>ì €í¬ëŠ” ìƒˆë¡œìš´ í¬ë˜ì»¤, ìƒˆë¡œìš´ í—´í”„ í¬íŠ¸í´ë¦¬ì˜¤, í™€í‘¸ë“œì™€ ê¸°íƒ€ ì†Œë§¤ì—…ì²´ì—ì„œ íŒë§¤ë˜ëŠ” ìƒˆë¡œìš´ ì œí’ˆë“¤ ë“± ë‹¤ì–‘í•œ ì‹ ì œí’ˆ ì¶œì‹œë¥¼ í†µí•´ ì›°ë‹ˆìŠ¤ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì§€ì†ì ìœ¼ë¡œ í™•ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ë¯¸êµ­ ì „ì—­ 17,000ê°œ ì´ìƒì˜ ì†Œë§¤ì—…ì²´ì— ì…ì í•´ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì œí’ˆë“¤ì€ ì•„ë§ˆì¡´ê³¼ ë‹¤ìˆ˜ì˜ ì˜¨ë¼ì¸ ì†Œë§¤ì—…ì²´ì—ì„œë„ ì¶œì‹œë˜ì—ˆìŠµë‹ˆë‹¤. ì €ëŠ” 2026ë…„ ë‚¨ì€ ê¸°ê°„ê³¼ ê·¸ ì´í›„ í‹¸ë ˆì´ì˜ ì „ë§ì— ëŒ€í•´ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìœ¼ë©°, ì €í¬ ì—…ê³„ì˜ ê·œì œ í™˜ê²½ì´ ì˜ë¯¸ ìˆëŠ” ë³€í™”ë¥¼ ì•ë‘ê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ê¸ì •ì ì¸ ë³€í™”ê°€ ìˆì„ ê²ƒìœ¼ë¡œ ì¶©ë¶„íˆ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì‹ ì†í•˜ê³  ì „ëµì ìœ¼ë¡œ ì ì‘í•  ìˆ˜ ìˆëŠ” ì €í¬ì˜ ëŠ¥ë ¥ì„ í™•ì‹ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Our proven approach, robust product portfolio and exceptional team position us to seize every single opportunity, especially in Wellness, where we see us with significant expansive opportunities, and we're committed to unlocking new possibilities through continuous innovation, portfolio expansion, targeted investments, including the opportunities when strategic acquisitions happen. While we've made considerable progress, we recognize we have not yet reached our full potential, and we're far from it in the Wellness space. And that is the same with our Cannabis business and our Beverage business. There's lots of room and lots of white space for us.</td><td>ìš°ë¦¬ì˜ ê²€ì¦ëœ ì ‘ê·¼ë²•, ê²¬ê³ í•œ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤, ê·¸ë¦¬ê³  íƒì›”í•œ íŒ€ì€ ëª¨ë“  ê¸°íšŒë¥¼ í¬ì°©í•  ìˆ˜ ìˆëŠ” ìœ„ì¹˜ì— ìˆê²Œ í•´ì£¼ë©°, íŠ¹íˆ ì›°ë‹ˆìŠ¤ ë¶„ì•¼ì—ì„œ ìƒë‹¹í•œ í™•ì¥ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì§€ì†ì ì¸ í˜ì‹ , í¬íŠ¸í´ë¦¬ì˜¤ í™•ì¥, ì „ëµì  ì¸ìˆ˜ ê¸°íšŒë¥¼ í¬í•¨í•œ íƒ€ê²Ÿ íˆ¬ìë¥¼ í†µí•´ ìƒˆë¡œìš´ ê°€ëŠ¥ì„±ì„ ì—´ì–´ê°€ëŠ” ë° ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ì—ˆì§€ë§Œ, ìš°ë¦¬ëŠ” ì•„ì§ ì™„ì „í•œ ì ì¬ë ¥ì— ë„ë‹¬í•˜ì§€ ëª»í–ˆë‹¤ëŠ” ê²ƒì„ ì¸ì‹í•˜ê³  ìˆìœ¼ë©°, ì›°ë‹ˆìŠ¤ ì˜ì—­ì—ì„œëŠ” ì•„ì§ ê°ˆ ê¸¸ì´ ë©‰ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì˜ ëŒ€ë§ˆì´ˆ ì‚¬ì—…ê³¼ ìŒë£Œ ì‚¬ì—…ì—ì„œë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ìš°ë¦¬ì—ê²ŒëŠ” ë§ì€ ì—¬ì§€ì™€ ë§ì€ ë¯¸ê°œì²™ ì˜ì—­ì´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With that, I will now turn the call over to Carl for an in-depth look at our financials. Carl? Carl Merton<br>CFO & Principal Accounting Officer<br><br>Thank you, Irwin. Please note that we present our financials in accordance with U.S. GAAP and in U.S. dollars. Throughout our discussions, we will be referring to both GAAP and non-GAAP adjusted results, and we encourage you to review the reconciliation contained within the press release of our reported results under GAAP with the corresponding non-GAAP measures. Now looking at our results, we are reporting record first quarter net revenue, net income and a significantly improved adjusted free cash flow for the period.</td><td>ì´ì œ ì¬ë¬´ ìƒí™©ì— ëŒ€í•œ ì‹¬ì¸µ ë¶„ì„ì„ ìœ„í•´ Carlì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. Carl?<br><br>Carl Merton<br>ìµœê³ ì¬ë¬´ì±…ì„ì ê²¸ ìˆ˜ì„íšŒê³„ì±…ì„ì<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Irwin. ì €í¬ëŠ” ë¯¸êµ­ íšŒê³„ê¸°ì¤€(U.S. GAAP)ì— ë”°ë¼ ë¯¸êµ­ ë‹¬ëŸ¬ë¡œ ì¬ë¬´ì œí‘œë¥¼ ì‘ì„±í•˜ì—¬ ë°œí‘œí•œë‹¤ëŠ” ì ì„ ë§ì”€ë“œë¦½ë‹ˆë‹¤. ë…¼ì˜ ê³¼ì •ì—ì„œ GAAP ê¸°ì¤€ê³¼ ë¹„GAAP ì¡°ì • ê²°ê³¼ë¥¼ ëª¨ë‘ ì–¸ê¸‰í•  ì˜ˆì •ì´ë©°, ë³´ë„ìë£Œì— í¬í•¨ëœ GAAP ê¸°ì¤€ ë³´ê³  ê²°ê³¼ì™€ í•´ë‹¹ ë¹„GAAP ì§€í‘œ ê°„ì˜ ì¡°ì •í‘œë¥¼ ê²€í† í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. <br><br>ì´ì œ ì‹¤ì ì„ ì‚´í´ë³´ë©´, 1ë¶„ê¸° ê¸°ì¤€ìœ¼ë¡œ ì‚¬ìƒ ìµœê³ ì˜ ìˆœë§¤ì¶œ, ìˆœì´ìµì„ ê¸°ë¡í–ˆìœ¼ë©°, í•´ë‹¹ ê¸°ê°„ ì¡°ì • ì‰ì—¬í˜„ê¸ˆíë¦„ë„ í¬ê²Œ ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Further, we are reaffirming our 2026 guidance for adjusted EBITDA. Net revenue for the first quarter was a record $210 million, a 5% increase year-over-year. This growth was driven primarily by increased cannabis sales in both Canada and our international markets and increased revenue in our distribution segment. Cannabis revenue increased 5% year-over-year to $64.5 million, driven by 12% growth of adult-use gross revenue and 10% growth in international cannabis. Higher excise taxes and declines in wholesale cannabis offset those double-digit results.</td><td>ë˜í•œ, ì €í¬ëŠ” 2026ë…„ ì¡°ì • EBITDA ê°€ì´ë˜ìŠ¤ë¥¼ ì¬í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. 1ë¶„ê¸° ìˆœë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 5% ì¦ê°€í•œ ê¸°ë¡ì ì¸ 2ì–µ 1ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ì€ ì£¼ë¡œ ìºë‚˜ë‹¤ì™€ í•´ì™¸ ì‹œì¥ì—ì„œì˜ ëŒ€ë§ˆì´ˆ íŒë§¤ ì¦ê°€, ê·¸ë¦¬ê³  ìœ í†µ ë¶€ë¬¸ì˜ ë§¤ì¶œ ì¦ê°€ì— ì˜í•´ ê²¬ì¸ë˜ì—ˆìŠµë‹ˆë‹¤. ëŒ€ë§ˆì´ˆ ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 5% ì¦ê°€í•œ 6,450ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì„±ì¸ìš© ì´ë§¤ì¶œì˜ 12% ì„±ì¥ê³¼ í•´ì™¸ ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì˜ 10% ì„±ì¥ì— ì˜í•´ ê²¬ì¸ë˜ì—ˆìŠµë‹ˆë‹¤. ë†’ì€ ì†Œë¹„ì„¸ì™€ ë„ë§¤ ëŒ€ë§ˆì´ˆ ë§¤ì¶œ ê°ì†Œê°€ ì´ëŸ¬í•œ ë‘ ìë¦¿ìˆ˜ ì„±ê³¼ë¥¼ ìƒì‡„í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We see material potential for the International segment and expect continued growth once we receive several permits that are currently backlogged in a few European countries. Beverage revenue reached $55.7 million, driven by innovation and impacted by continued SKU rationalization. We advanced Project 420 and integrated acquired brands. Although craft brands and spirits faced challenges, new products contributed 2% to Q1 revenue, supporting our belief in the beverage category's long-term growth.</td><td>êµ­ì œ ë¶€ë¬¸ì—ì„œ ìƒë‹¹í•œ ì ì¬ë ¥ì„ ë³´ê³  ìˆìœ¼ë©°, í˜„ì¬ ëª‡ëª‡ ìœ ëŸ½ êµ­ê°€ì—ì„œ ì ì²´ë˜ì–´ ìˆëŠ” ì—¬ëŸ¬ í—ˆê°€ë¥¼ ë°›ê²Œ ë˜ë©´ ì§€ì†ì ì¸ ì„±ì¥ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìŒë£Œ ë§¤ì¶œì€ í˜ì‹ ì— í˜ì…ì–´ 5,570ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì§€ì†ì ì¸ SKU í•©ë¦¬í™”ì˜ ì˜í–¥ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. í”„ë¡œì íŠ¸ 420ì„ ì§„ì „ì‹œí‚¤ê³  ì¸ìˆ˜í•œ ë¸Œëœë“œë“¤ì„ í†µí•©í–ˆìŠµë‹ˆë‹¤. ìˆ˜ì œ ë¸Œëœë“œì™€ ì£¼ë¥˜ ë¶€ë¬¸ì´ ì–´ë ¤ì›€ì— ì§ë©´í–ˆì§€ë§Œ, ì‹ ì œí’ˆì´ 1ë¶„ê¸° ë§¤ì¶œì— 2% ê¸°ì—¬í•˜ì—¬ ìŒë£Œ ì¹´í…Œê³ ë¦¬ì˜ ì¥ê¸°ì  ì„±ì¥ì— ëŒ€í•œ ì €í¬ì˜ ë¯¿ìŒì„ ë’·ë°›ì¹¨í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Wellness revenue increased 3% year-over-year to $15.2 million because of our strategic focus on continued innovations with HiBall energy, our natural energy drink, high-protein super seeds and better-for-you breakfast and snacking, including the launch of 2 new offerings from Manitoba Harvest at Whole Foods. Distribution revenue increased 9% year-over-year to $74 million in the quarter, primarily as a result of the stronger euro. From a contribution perspective, 31% of net revenue was generated by our Cannabis business, 27% was generated by our Beverage business, 7% was generated by our Wellness business and 35% was generated by our Distribution business.</td><td>ì›°ë‹ˆìŠ¤ ë§¤ì¶œì€ ìì—° ì—ë„ˆì§€ ìŒë£Œì¸ HiBall ì—ë„ˆì§€, ê³ ë‹¨ë°± ìŠˆí¼ ì‹œë“œ, ê·¸ë¦¬ê³  í™€í‘¸ì¦ˆì—ì„œ ì¶œì‹œëœ Manitoba Harvestì˜ 2ê°€ì§€ ì‹ ì œí’ˆì„ í¬í•¨í•œ ë” ë‚˜ì€ ì•„ì¹¨ì‹ì‚¬ ë° ê°„ì‹ ì œí’ˆì— ëŒ€í•œ ì§€ì†ì ì¸ í˜ì‹ ì— ì „ëµì ìœ¼ë¡œ ì§‘ì¤‘í•œ ê²°ê³¼, ì „ë…„ ë™ê¸° ëŒ€ë¹„ 3% ì¦ê°€í•œ 1,520ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ìœ í†µ ë§¤ì¶œì€ ì£¼ë¡œ ìœ ë¡œí™” ê°•ì„¸ì˜ ì˜í–¥ìœ¼ë¡œ ë¶„ê¸° ì¤‘ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 9% ì¦ê°€í•œ 7,400ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ê¸°ì—¬ë„ ê´€ì ì—ì„œ ë³´ë©´, ìˆœë§¤ì¶œì˜ 31%ëŠ” ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì—ì„œ, 27%ëŠ” ìŒë£Œ ì‚¬ì—…ì—ì„œ, 7%ëŠ” ì›°ë‹ˆìŠ¤ ì‚¬ì—…ì—ì„œ, ê·¸ë¦¬ê³  35%ëŠ” ìœ í†µ ì‚¬ì—…ì—ì„œ ì°½ì¶œë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This compares to contributions of approximately 31% for Cannabis, 28% for Beverage, 7% for Wellness and 34% for Distribution in the last fiscal quarter. As our International Cannabis business continues to expand, we expect to see higher contributions from our Cannabis segment over the remainder of the year. Gross profit for the quarter was $57.5 million compared to $59.7 million in the prior year period. Gross margin was 27% as compared to 30% last year. This decline was driven by lower margins in our Beverage and Cannabis businesses. Looking at gross margin by segment.</td><td>ì´ëŠ” ì§€ë‚œ íšŒê³„ë¶„ê¸°ì˜ ëŒ€ë§ˆì´ˆ ì•½ 31%, ìŒë£Œ 28%, ì›°ë‹ˆìŠ¤ 7%, ìœ í†µ 34% ê¸°ì—¬ë„ì™€ ë¹„êµë˜ëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ êµ­ì œ ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì´ ì§€ì†ì ìœ¼ë¡œ í™•ì¥ë¨ì— ë”°ë¼, ì˜¬í•´ ë‚¨ì€ ê¸°ê°„ ë™ì•ˆ ëŒ€ë§ˆì´ˆ ë¶€ë¬¸ì˜ ê¸°ì—¬ë„ê°€ ë”ìš± ë†’ì•„ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì´ì´ìµì€ 5,750ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° 5,970ë§Œ ë‹¬ëŸ¬ì™€ ë¹„êµë©ë‹ˆë‹¤. ì´ì´ìµë¥ ì€ 27%ë¡œ ì‘ë…„ 30%ì™€ ë¹„êµë©ë‹ˆë‹¤. ì´ëŸ¬í•œ ê°ì†ŒëŠ” ìŒë£Œ ë° ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì˜ ë§ˆì§„ í•˜ë½ì— ê¸°ì¸í•©ë‹ˆë‹¤. ë¶€ë¬¸ë³„ ì´ì´ìµë¥ ì„ ì‚´í´ë³´ë©´.</td></tr>
<tr><td>Cannabis gross margin was 36% compared to 40% last year as a result of a higher mix of sales in lower-margin categories such as infused pre-rolls and vapes, where we reentered some previously margin-prohibitive categories. We believe the decline this quarter is temporary and the actions we have taken to drive profitability and improve margins will be effective in the long term. Beverage gross margin was 38% compared to 41% last year. The decrease in gross margin is due to the inclusion of [ craft acquisition to ] sales, which have generally been lower margin. Wellness gross margin was flat year-over-year at 32%.</td><td>ëŒ€ë§ˆì´ˆ ë¶€ë¬¸ì˜ ë§¤ì¶œì´ì´ìµë¥ ì€ 36%ë¡œ ì „ë…„ ë™ê¸° 40% ëŒ€ë¹„ í•˜ë½í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¸í“¨ì¦ˆë“œ í”„ë¦¬ë¡¤ê³¼ ë² ì´í”„ ë“± ì €ë§ˆì§„ ì¹´í…Œê³ ë¦¬ì˜ ë§¤ì¶œ ë¹„ì¤‘ì´ ë†’ì•„ì§„ ê²°ê³¼ë¡œ, ë‹¹ì‚¬ëŠ” ì´ì „ì— ë§ˆì§„ ì œì•½ìœ¼ë¡œ ì¸í•´ ì§„ì…í•˜ì§€ ëª»í–ˆë˜ ì¼ë¶€ ì¹´í…Œê³ ë¦¬ì— ì¬ì§„ì…í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì´ë²ˆ ë¶„ê¸°ì˜ í•˜ë½ì€ ì¼ì‹œì ì¸ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìœ¼ë©°, ìˆ˜ìµì„± ì œê³ ì™€ ë§ˆì§„ ê°œì„ ì„ ìœ„í•´ ì·¨í•œ ì¡°ì¹˜ë“¤ì´ ì¥ê¸°ì ìœ¼ë¡œ íš¨ê³¼ì ì¼ ê²ƒì´ë¼ê³  ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ìŒë£Œ ë¶€ë¬¸ì˜ ë§¤ì¶œì´ì´ìµë¥ ì€ 38%ë¡œ ì „ë…„ ë™ê¸° 41% ëŒ€ë¹„ í•˜ë½í–ˆìŠµë‹ˆë‹¤. ë§¤ì¶œì´ì´ìµë¥  ê°ì†ŒëŠ” ì¼ë°˜ì ìœ¼ë¡œ ë§ˆì§„ì´ ë‚®ì€ [í¬ë˜í”„íŠ¸ ì¸ìˆ˜] ë§¤ì¶œì´ í¬í•¨ëœ ê²ƒì´ ì›ì¸ì…ë‹ˆë‹¤. <br><br>ì›°ë‹ˆìŠ¤ ë¶€ë¬¸ì˜ ë§¤ì¶œì´ì´ìµë¥ ì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 32%ë¡œ ë™ì¼í•œ ìˆ˜ì¤€ì„ ìœ ì§€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Distribution gross margin was 11% compared to 12% last year based on changes in product mix. Net income was $1.5 million or $0.00 per share compared to a net loss of $34.7 million or negative 4% per share in the prior year period. Adjusted net income improved to $3.9 million or $0.00 per share compared to an adjusted net loss of $6 million or negative $0.01 per share in the prior year. Improvements in both metrics were a function of reduced SG&A costs, including amortization. Adjusted EBITDA for the quarter was $10.2 million compared to $9.3 million last year.</td><td>ìœ í†µ ì´ë§ˆì§„ì€ ì œí’ˆ ë¯¹ìŠ¤ ë³€í™”ë¡œ ì¸í•´ ì‘ë…„ 12% ëŒ€ë¹„ 11%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ìˆœì´ìµì€ 150ë§Œ ë‹¬ëŸ¬ ë˜ëŠ” ì£¼ë‹¹ 0.00ë‹¬ëŸ¬ë¡œ, ì „ë…„ ë™ê¸° ìˆœì†ì‹¤ 3,470ë§Œ ë‹¬ëŸ¬ ë˜ëŠ” ì£¼ë‹¹ ë§ˆì´ë„ˆìŠ¤ 4% ëŒ€ë¹„ ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤. ì¡°ì • ìˆœì´ìµì€ 390ë§Œ ë‹¬ëŸ¬ ë˜ëŠ” ì£¼ë‹¹ 0.00ë‹¬ëŸ¬ë¡œ ê°œì„ ë˜ì–´, ì „ë…„ ë™ê¸° ì¡°ì • ìˆœì†ì‹¤ 600ë§Œ ë‹¬ëŸ¬ ë˜ëŠ” ì£¼ë‹¹ ë§ˆì´ë„ˆìŠ¤ 0.01ë‹¬ëŸ¬ì™€ ë¹„êµë©ë‹ˆë‹¤. ë‘ ì§€í‘œ ëª¨ë‘ì˜ ê°œì„ ì€ ìƒê°ë¹„ë¥¼ í¬í•¨í•œ íŒë§¤ê´€ë¦¬ë¹„ ì ˆê°ì— ê¸°ì¸í•©ë‹ˆë‹¤. ë¶„ê¸° ì¡°ì • EBITDAëŠ” ì‘ë…„ 930ë§Œ ë‹¬ëŸ¬ ëŒ€ë¹„ 1,020ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Cash flow used in operations improved significantly to negative $1.3 million for the quarter from negative $35.3 million last year, representing a positive change of almost $35 million. We continue to strengthen our balance sheet this quarter in terms of debt and cash positions. During the quarter, we raised $22.5 million under our ATM program, primarily after our stock increased to over $1 per share. Further, we exchanged $5 million of our convertible notes for equity early in the quarter, as we already discussed during our last earnings call.</td><td>ì´ë²ˆ ë¶„ê¸° ì˜ì—…í™œë™ìœ¼ë¡œ ì¸í•œ í˜„ê¸ˆíë¦„ì€ ì‘ë…„ ë§ˆì´ë„ˆìŠ¤ 3,530ë§Œ ë‹¬ëŸ¬ì—ì„œ ë§ˆì´ë„ˆìŠ¤ 130ë§Œ ë‹¬ëŸ¬ë¡œ í¬ê²Œ ê°œì„ ë˜ì–´, ê±°ì˜ 3,500ë§Œ ë‹¬ëŸ¬ì— ë‹¬í•˜ëŠ” ê¸ì •ì ì¸ ë³€í™”ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì—ë„ ë¶€ì±„ì™€ í˜„ê¸ˆ í¬ì§€ì…˜ ì¸¡ë©´ì—ì„œ ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ì§€ì†ì ìœ¼ë¡œ ê°•í™”í–ˆìŠµë‹ˆë‹¤. ë¶„ê¸° ì¤‘ì—ëŠ” ì£¼ê°€ê°€ ì£¼ë‹¹ 1ë‹¬ëŸ¬ë¥¼ ë„˜ì–´ì„  ì´í›„ë¥¼ ì¤‘ì‹¬ìœ¼ë¡œ ATM í”„ë¡œê·¸ë¨ì„ í†µí•´ 2,250ë§Œ ë‹¬ëŸ¬ë¥¼ ì¡°ë‹¬í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ì§€ë‚œ ì‹¤ì ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ì½œì—ì„œ ì´ë¯¸ ë…¼ì˜í–ˆë“¯ì´, ë¶„ê¸° ì´ˆì— ì „í™˜ì‚¬ì±„ 500ë§Œ ë‹¬ëŸ¬ë¥¼ ì§€ë¶„ìœ¼ë¡œ êµí™˜í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>During the quarter, we reduced our outstanding debt by $7.7 million, bringing our net debt position down to $3.9 million and our net debt to trailing 12 months adjusted EBITDA ratio to 0.07x, all while ending the quarter with $265 million in cash plus another $1 million in digital assets. These stronger debt and cash positions provide Tilray with greater flexibility for strategic opportunities, and we intend to continue reducing our debt and further strengthening our balance sheet as the year progresses.</td><td>ì´ë²ˆ ë¶„ê¸° ë™ì•ˆ ë‹¹ì‚¬ëŠ” ë¯¸ìƒí™˜ ë¶€ì±„ë¥¼ 770ë§Œ ë‹¬ëŸ¬ ê°ì¶•í•˜ì—¬ ìˆœë¶€ì±„ í¬ì§€ì…˜ì„ 390ë§Œ ë‹¬ëŸ¬ë¡œ ë‚®ì·„ìœ¼ë©°, ìˆœë¶€ì±„ ëŒ€ë¹„ í›„í–‰ 12ê°œì›” ì¡°ì • EBITDA ë¹„ìœ¨ì„ 0.07ë°°ë¡œ ê°œì„ í–ˆìŠµë‹ˆë‹¤. ë™ì‹œì— ë¶„ê¸°ë§ ê¸°ì¤€ìœ¼ë¡œ í˜„ê¸ˆ 2ì–µ 6,500ë§Œ ë‹¬ëŸ¬ì™€ ë””ì§€í„¸ ìì‚° 100ë§Œ ë‹¬ëŸ¬ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²¬ê³ í•œ ë¶€ì±„ ë° í˜„ê¸ˆ í¬ì§€ì…˜ì€ Tilrayì—ê²Œ ì „ëµì  ê¸°íšŒì— ëŒ€í•œ ë” í° ìœ ì—°ì„±ì„ ì œê³µí•˜ë©°, ì˜¬í•´ê°€ ì§„í–‰ë¨ì— ë”°ë¼ ë¶€ì±„ë¥¼ ì§€ì†ì ìœ¼ë¡œ ì¤„ì´ê³  ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ë”ìš± ê°•í™”í•´ ë‚˜ê°ˆ ê³„íšì…ë‹ˆë‹¤.</td></tr>
<tr><td>As already discussed, our confidence in our business, our strategy and our team has never been higher, and we are pleased to reaffirm our 2026 guidance, anticipating adjusted EBITDA between $62 million and $72 million. We can now open the line for Q&A.</td><td>ì´ë¯¸ ë…¼ì˜í•œ ë°”ì™€ ê°™ì´, ì €í¬ ì‚¬ì—…, ì „ëµ, ê·¸ë¦¬ê³  íŒ€ì— ëŒ€í•œ í™•ì‹ ì€ ê·¸ ì–´ëŠ ë•Œë³´ë‹¤ ë†’ìœ¼ë©°, 2026ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ì¬í™•ì¸í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ì¡°ì • EBITDAëŠ” 6,200ë§Œ ë‹¬ëŸ¬ì—ì„œ 7,200ë§Œ ë‹¬ëŸ¬ ì‚¬ì´ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Here's a summary of the Tilray Brands Q1 2026 earnings call in Korean:<br><br>â€¢ ì¬ë¬´ ì‹¤ì <br>- Q1 ë§¤ì¶œ ì „ë…„ ëŒ€ë¹„ 5% ì¦ê°€í•œ 2ì–µ 1ì²œë§Œ ë‹¬ëŸ¬ ê¸°ë¡<br>- ìˆœì´ìµ 150ë§Œ ë‹¬ëŸ¬ ë‹¬ì„± (ì£¼ë‹¹ìˆœì´ìµ 0ë‹¬ëŸ¬)<br>- í˜„ê¸ˆ ë° í˜„ê¸ˆì„±ìì‚° 2ì–µ 6,500ë§Œ ë‹¬ëŸ¬ ë³´ìœ <br>- ë¶€ì±„ 770ë§Œ ë‹¬ëŸ¬ ê°ì†Œ<br><br>â€¢ ì‚¬ì—…ë¶€ë¬¸ë³„ ì„±ê³¼<br>- ìºë‚˜ë¹„ìŠ¤ ë¶€ë¬¸: ì „ë…„ ëŒ€ë¹„ 5% ì„±ì¥, ìºë‚˜ë‹¤ ì„±ì¸ìš© ì‹œì¥ì—ì„œ 12% ì„±ì¥<br>- êµ­ì œ ìºë‚˜ë¹„ìŠ¤: 10% ì„±ì¥í•œ 1,340ë§Œ ë‹¬ëŸ¬ ê¸°ë¡<br>- ìŒë£Œ ë¶€ë¬¸: SKU í•©ë¦¬í™”ë¡œ ì¸í•´ ë§¤ì¶œ ì •ì²´<br>- ìœ í†µ ë¶€ë¬¸: CC Pharma í†µí•´ 9% ì„±ì¥í•œ 7,400ë§Œ ë‹¬ëŸ¬ ë‹¬ì„±<br><br>â€¢ ì „ëµì  ì´ˆì <br>- ë¯¸êµ­ ì˜ë£Œìš© ìºë‚˜ë¹„ìŠ¤ ì‹œì¥ ì§„ì¶œ ì¤€ë¹„ (ì ì¬ì  3-5% ì‹œì¥ì ìœ ìœ¨ ëª©í‘œ)<br>- Project 420ë¥¼ í†µí•œ ì—°ê°„ 2,500ë§Œ ë‹¬ëŸ¬ ë¹„ìš©ì ˆê° ë‹¬ì„±<br>- êµ­ì œ ì‹œì¥ í™•ëŒ€ì— ì§‘ì¤‘, íŠ¹íˆ ìœ ëŸ½ì—ì„œì˜ ì„±ì¥ ê¸°íšŒ ëª¨ìƒ‰<br><br>ì´ ë‚´ìš©ì€ ì „ë¬¸ íˆ¬ììë“¤ì„ ìœ„í•´ ì£¼ìš” ì¬ë¬´ì§€í‘œ, ì‚¬ì—… ì„±ê³¼, ê²½ì˜ì§„ì˜ ì „ëµì  ë°©í–¥ì„±ì„ ê°ê´€ì ìœ¼ë¡œ ìš”ì•½í•œ ê²ƒì…ë‹ˆë‹¤.</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Our first question comes from Aaron Grey with Alliance Global Partners.</td><td>**Operator:** [ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ Alliance Global Partnersì˜ Aaron Greyë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Aaron Grey: Alliance Global Partners, Research Division First question for me. I just want to talk a little bit about international growth opportunities in the near term. You offered some commentary in your prepared remarks. I just want to make sure I was understanding them correctly. So first of all, just further understanding in terms of where we stand today in terms of the impact on some of the permit delays that you've been having. And then some commentary you provided in terms of the growth, specifically, I think you're referring to medical cannabis business up 3x in fiscal year 2026 and talks about leveraging CC Pharma potential. I just want to make sure I was understanding that correctly. Were there some things that you're looking to leverage with CC Pharma business that you were not historically? So just any additional commentary on that would be helpful.</td><td>**Aaron Grey:** ë¨¼ì € ë‹¨ê¸° êµ­ì œ ì„±ì¥ ê¸°íšŒì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ì¤€ë¹„ëœ ë°œì–¸ì—ì„œ ëª‡ ê°€ì§€ ì–¸ê¸‰í•´ ì£¼ì…¨ëŠ”ë°, ì œëŒ€ë¡œ ì´í•´í–ˆëŠ”ì§€ í™•ì¸í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ìš°ì„  í˜„ì¬ ê²ªê³  ê³„ì‹  í—ˆê°€ ì§€ì—°ì˜ ì˜í–¥ê³¼ ê´€ë ¨í•´ì„œ í˜„ì¬ ìƒí™©ì´ ì–´ë–¤ì§€ ì¢€ ë” ìì„¸íˆ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì„±ì¥ì— ëŒ€í•œ ì–¸ê¸‰ ì¤‘ì—ì„œ, íŠ¹íˆ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì´ 2026 íšŒê³„ì—°ë„ì— 3ë°° ì„±ì¥í•  ê²ƒì´ë¼ê³  í•˜ì…¨ê³  CC Pharmaì˜ ì ì¬ë ¥ í™œìš©ì— ëŒ€í•´ì„œë„ ë§ì”€í•˜ì‹  ê²ƒ ê°™ì€ë°, ì œëŒ€ë¡œ ì´í•´í•œ ê²Œ ë§ëŠ”ì§€ í™•ì¸í•´ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤. CC Pharma ì‚¬ì—…ê³¼ ê´€ë ¨í•´ì„œ ê³¼ê±°ì—ëŠ” í™œìš©í•˜ì§€ ëª»í–ˆë˜ ë¶€ë¶„ë“¤ì„ ì´ì œ ë ˆë²„ë¦¬ì§€í•˜ë ¤ê³  í•˜ëŠ” ê²ƒë“¤ì´ ìˆëŠ”ì§€ìš”? ê·¸ ë¶€ë¶„ì— ëŒ€í•œ ì¶”ê°€ì ì¸ ì„¤ëª…ì„ í•´ì£¼ì‹œë©´ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Irwin Simon: President, CEO & Chairman Great. So a couple of your questions. Number one, in regards to permits, we spent a lot of time with the Portuguese government. We've spent a lot of time in Portugal. We're finally seeing permits coming through. And I feel good about that. Where the next big issue that we run into is the quota in Germany and just Germany opening up and increasing more imports into the German market, which we think ultimately, that will happen. But it's not business going away. It just may shift from second quarter into third quarter, as the new quotas move into place in 2026. So with that, I feel we've made a lot of headway into the Portuguese permit situation. And we got more permits in the last 2 weeks than we've probably got in the last 2 months or so. In regards to a couple of things, the demand in Europe is there. And with that, it's the availability and the growth. And with the team, and now we have moved some of the Canadian team into international. We look to grow and our facility today in Portugal is running about 50%. We have the opportunity to double that at 40 metric tons, and that's something we're working on. The other thing is to really increase our growth to probably 6 or 8 metric tons in our German facility. And also where the opportunity is in regards to bringing product, EU GMP product in from the Canadian market. In regards to Germany, what I've said and what I was working through, CC Pharma, when we acquired it, it was a big part of our license and it was something that there was an opportunity. And what we're seeing is some great expansion with CC Pharma. CC Pharma delivers to 13,000 drug stores today, and that is regular medicines, and the good thing is we're also seeing some good price increase and some good opportunities on the CC Pharma Distribution business. But more importantly, as we integrate these businesses, whether it is on the sales side and the Distribution side, we see CC Pharma being vertically integrated and distributing our medical cannabis to a lot more of these drug stores in the German market, and that's a big opportunity for us.</td><td>**Irwin Simon:** ëª‡ ê°€ì§€ ì§ˆë¬¸ì— ëŒ€í•´ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì²«ì§¸, í—ˆê°€ì™€ ê´€ë ¨í•´ì„œëŠ” í¬ë¥´íˆ¬ê°ˆ ì •ë¶€ì™€ ë§ì€ ì‹œê°„ì„ ë³´ëƒˆìŠµë‹ˆë‹¤. í¬ë¥´íˆ¬ê°ˆì—ì„œ ìƒë‹¹í•œ ì‹œê°„ì„ íˆ¬ìí–ˆê³ , ë§ˆì¹¨ë‚´ í—ˆê°€ê°€ ë‚˜ì˜¤ê¸° ì‹œì‘í•˜ëŠ” ê²ƒì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ì„œëŠ” ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë‹¤ìŒìœ¼ë¡œ ì§ë©´í•œ í° ì´ìŠˆëŠ” ë…ì¼ì˜ ì¿¼í„° ë¬¸ì œì…ë‹ˆë‹¤. ë…ì¼ì´ ë¬¸í˜¸ë¥¼ ê°œë°©í•˜ê³  ë…ì¼ ì‹œì¥ìœ¼ë¡œì˜ ìˆ˜ì…ì„ ëŠ˜ë¦¬ëŠ” ê²ƒì¸ë°, ê¶ê·¹ì ìœ¼ë¡œëŠ” ê·¸ë ‡ê²Œ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì‚¬ì—…ì´ ì‚¬ë¼ì§€ëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. 2026ë…„ì— ìƒˆë¡œìš´ ì¿¼í„°ê°€ ì‹œí–‰ë˜ë©´ì„œ 2ë¶„ê¸°ì—ì„œ 3ë¶„ê¸°ë¡œ ì‹œê¸°ê°€ ì´ë™í•  ìˆ˜ë„ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. <br><br>ê·¸ëŸ° ì ì—ì„œ í¬ë¥´íˆ¬ê°ˆ í—ˆê°€ ìƒí™©ì—ì„œëŠ” ìƒë‹¹í•œ ì§„ì „ì„ ì´ë¤˜ë‹¤ê³  ë´…ë‹ˆë‹¤. ì§€ë‚œ 2ì£¼ ë™ì•ˆ ë°›ì€ í—ˆê°€ê°€ ì•„ë§ˆë„ ì§€ë‚œ 2ê°œì›” ì •ë„ ë™ì•ˆ ë°›ì€ ê²ƒë³´ë‹¤ ë” ë§ì„ ê²ƒì…ë‹ˆë‹¤. ëª‡ ê°€ì§€ ì‚¬ì•ˆì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë©´, ìœ ëŸ½ì˜ ìˆ˜ìš”ëŠ” ë¶„ëª…íˆ ì¡´ì¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì™€ í•¨ê»˜ ê°€ìš©ì„±ê³¼ ì„±ì¥ì´ ì¤‘ìš”í•œ ìš”ì†Œì…ë‹ˆë‹¤. íŒ€ê³¼ ê´€ë ¨í•´ì„œëŠ” í˜„ì¬ ìºë‚˜ë‹¤ íŒ€ ì¼ë¶€ë¥¼ êµ­ì œ ë¶€ë¬¸ìœ¼ë¡œ ì´ë™ì‹œì¼°ê³ , ì„±ì¥ì„ ë„ëª¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ í¬ë¥´íˆ¬ê°ˆ ì‹œì„¤ì€ ì•½ 50% ê°€ë™ë¥ ë¡œ ìš´ì˜ë˜ê³  ìˆìŠµë‹ˆë‹¤. 40ë¯¸í„°í†¤ê¹Œì§€ ë‘ ë°°ë¡œ ëŠ˜ë¦´ ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìˆìœ¼ë©°, ì´ëŠ” í˜„ì¬ ì‘ì—… ì¤‘ì¸ ë¶€ë¶„ì…ë‹ˆë‹¤. ë˜ ë‹¤ë¥¸ ì‚¬ì•ˆì€ ë…ì¼ ì‹œì„¤ì—ì„œ ìƒì‚°ëŸ‰ì„ 6~8ë¯¸í„°í†¤ ì •ë„ë¡œ ì‹¤ì§ˆì ìœ¼ë¡œ ì¦ëŒ€ì‹œí‚¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìºë‚˜ë‹¤ ì‹œì¥ì—ì„œ EU GMP ì œí’ˆì„ ë“¤ì—¬ì˜¤ëŠ” ê¸°íšŒë„ ìˆìŠµë‹ˆë‹¤. ë…ì¼ê³¼ ê´€ë ¨í•´ì„œëŠ” ì œê°€ ë§ì”€ë“œë ¸ê³  ì‘ì—…í•´ì™”ë˜ ë¶€ë¶„ì¸ë°, CC Pharmaë¥¼ ì¸ìˆ˜í–ˆì„ ë•Œ ì´ê²ƒì´ ì €í¬ ë¼ì´ì„ ìŠ¤ì˜ í° ë¶€ë¶„ì„ ì°¨ì§€í–ˆê³  ê¸°íšŒê°€ ìˆëŠ” ì˜ì—­ì´ì—ˆìŠµë‹ˆë‹¤. í˜„ì¬ CC Pharmaì™€ í•¨ê»˜ í›Œë¥­í•œ í™•ì¥ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. CC PharmaëŠ” ì˜¤ëŠ˜ë‚  13,000ê°œì˜ ì•½êµ­ì— ì¼ë°˜ ì˜ì•½í’ˆì„ ê³µê¸‰í•˜ê³  ìˆìœ¼ë©°, ì¢‹ì€ ì ì€ CC Pharma ìœ í†µ ì‚¬ì—…ì—ì„œ ê°€ê²© ì¸ìƒê³¼ ì¢‹ì€ ê¸°íšŒë“¤ì„ ë³´ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ë” ì¤‘ìš”í•œ ê²ƒì€, ì´ëŸ¬í•œ ì‚¬ì—…ë“¤ì„ í†µí•©í•˜ë©´ì„œ - íŒë§¤ ì¸¡ë©´ì´ë“  ìœ í†µ ì¸¡ë©´ì´ë“  - CC Pharmaê°€ ìˆ˜ì§ í†µí•©ë˜ì–´ ë…ì¼ ì‹œì¥ì˜ í›¨ì”¬ ë” ë§ì€ ì•½êµ­ë“¤ì— ìš°ë¦¬ì˜ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆë¥¼ ìœ í†µí•˜ëŠ” ê²ƒì„ ë³´ê³  ìˆë‹¤ëŠ” ì ì´ë©°, ì´ê²ƒì´ ìš°ë¦¬ì—ê²ŒëŠ” í° ê¸°íšŒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Unknown Analyst: That's helpful color there. Second question for me, just in terms of rescheduling opportunities in the U.S. You offered some commentary talking about seeing a number of different avenues that you guys are evaluating. Just curious, could you provide some color there? If things were to open up and cannabis was rescheduled to Schedule III. Do you feel like you already have the infrastructure within the existing business to be able to capture some of the opportunity organically? Or do you like some things that might need to be done vis-a-vis acquisition, to capture on that opportunity? I know there's a lot influx in terms of how that could actually look in a Schedule III scenario, but just any commentary on that would be greatly appreciated.</td><td>**Unknown Analyst:** ë„ì›€ì´ ë˜ëŠ” ì„¤ëª…ì´ì—ˆìŠµë‹ˆë‹¤. ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ ë¯¸êµ­ ë‚´ ì¬ë¶„ë¥˜ ê¸°íšŒì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì—¬ëŸ¬ ê°€ì§€ ë‹¤ì–‘í•œ ë°©í–¥ì„ í‰ê°€í•˜ê³  ìˆë‹¤ê³  ì–¸ê¸‰í•˜ì…¨ëŠ”ë°, ì¢€ ë” ìì„¸í•œ ì„¤ëª…ì„ í•´ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ë§Œì•½ ìƒí™©ì´ ê°œì„ ë˜ê³  ëŒ€ë§ˆì´ˆê°€ Schedule IIIë¡œ ì¬ë¶„ë¥˜ëœë‹¤ë©´, ê¸°ì¡´ ì‚¬ì—… ë‚´ì—ì„œ ì´ë¯¸ ê·¸ëŸ° ê¸°íšŒë¥¼ ìœ ê¸°ì ìœ¼ë¡œ í¬ì°©í•  ìˆ˜ ìˆëŠ” ì¸í”„ë¼ë¥¼ ê°–ì¶”ê³  ìˆë‹¤ê³  ë³´ì‹œë‚˜ìš”? ì•„ë‹ˆë©´ ê·¸ëŸ° ê¸°íšŒë¥¼ ì¡ê¸° ìœ„í•´ ì¸ìˆ˜í•©ë³‘ ê°™ì€ ì¡°ì¹˜ë“¤ì´ í•„ìš”í•  ê²ƒ ê°™ë‚˜ìš”? Schedule III ì‹œë‚˜ë¦¬ì˜¤ì—ì„œ ì‹¤ì œë¡œ ì–´ë–¤ ëª¨ìŠµì´ ë ì§€ì— ëŒ€í•´ì„œëŠ” ì•„ì§ ìœ ë™ì ì¸ ë¶€ë¶„ì´ ë§ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆì§€ë§Œ, ì´ì— ëŒ€í•œ ì–´ë–¤ ì˜ê²¬ì´ë¼ë„ ë“¤ë ¤ì£¼ì‹œë©´ ì •ë§ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Irwin Simon: President, CEO & Chairman Well, listen, as I've said before, we have 5 million square feet. We have today over 200-plus million metric tons of cannabis grow in Canada. We have a great Canadian medical infrastructure in Canada already servicing the Canadian market. Canadian market is 40 million people. So we service clinics up there. We have a group and an infrastructure that sells to the Canadian market today. Talking about Europe, as we look to sell and our objective is to sell close to $100 million of medical cannabis in Europe, which is all medical cannabis, and there's plenty of research that we're doing over there for anxiety, for sleep, for cancer, for epilepsy. So taking that know-how and transferring into the U.S. is something that's readily available. And last but not least, if there was an opportunity to partner with pharma company or there was something an opportunity for us to buy, we'd be ready and willing to enable to do that as we have the balance sheet potentially -- as we have the balance sheet to do that. So whether it's taking our current infrastructure, our current people, our current know-how, our current growth, our current research, our current genetics for medicine or partnering with a pharma company or buying something is something we're open and ready to do.</td><td>**Irwin Simon:** ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì €í¬ëŠ” 500ë§Œ í‰ë°©í”¼íŠ¸ ê·œëª¨ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ìºë‚˜ë‹¤ì—ì„œ 2ì–µ ë©”íŠ¸ë¦­í†¤ ì´ìƒì˜ ëŒ€ë§ˆì´ˆë¥¼ ì¬ë°°í•˜ê³  ìˆê³ ìš”. ì´ë¯¸ ìºë‚˜ë‹¤ ì‹œì¥ì— ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ëŠ” í›Œë¥­í•œ ìºë‚˜ë‹¤ ì˜ë£Œìš© ì¸í”„ë¼ë¥¼ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ìºë‚˜ë‹¤ ì‹œì¥ì€ 4ì²œë§Œ ëª… ê·œëª¨ì£ . ê·¸ê³³ì—ì„œ í´ë¦¬ë‹‰ë“¤ì— ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ê³  ìˆê³ , í˜„ì¬ ìºë‚˜ë‹¤ ì‹œì¥ì— íŒë§¤í•˜ëŠ” ê·¸ë£¹ê³¼ ì¸í”„ë¼ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ìœ ëŸ½ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë©´, ì €í¬ ëª©í‘œëŠ” ìœ ëŸ½ì—ì„œ ì•½ 1ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆë¥¼ íŒë§¤í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ëª¨ë‘ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆì´ê³ , ë¶ˆì•ˆ, ìˆ˜ë©´, ì•”, ê°„ì§ˆ ë“±ì— ëŒ€í•œ ë‹¤ì–‘í•œ ì—°êµ¬ë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë…¸í•˜ìš°ì™€ ì§€ì‹ì„ ë¯¸êµ­ìœ¼ë¡œ ì´ì „í•˜ëŠ” ê²ƒì€ ì¶©ë¶„íˆ ê°€ëŠ¥í•œ ì¼ì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì œì•½íšŒì‚¬ì™€ íŒŒíŠ¸ë„ˆì‹­ ê¸°íšŒê°€ ìˆê±°ë‚˜ ì¸ìˆ˜í•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìˆë‹¤ë©´ ì €í¬ëŠ” ì¤€ë¹„ë˜ì–´ ìˆê³  ê¸°êº¼ì´ ê·¸ë ‡ê²Œ í•  ì˜í–¥ì´ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê·¸ëŸ° ì¼ì„ í•  ìˆ˜ ìˆëŠ” ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ë³´ìœ í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ í˜„ì¬ì˜ ì¸í”„ë¼, ì¸ë ¥, ë…¸í•˜ìš°, ì„±ì¥, ì—°êµ¬, ì˜í•™ ìœ ì „í•™ì„ í™œìš©í•˜ë“ , ì œì•½íšŒì‚¬ì™€ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºë“ , ì•„ë‹ˆë©´ ë¬´ì–¸ê°€ë¥¼ ì¸ìˆ˜í•˜ë“  - ì´ ëª¨ë“  ê²ƒì— ëŒ€í•´ ì €í¬ëŠ” ì—´ë ¤ìˆê³  ì¤€ë¹„ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from the line of Bill Kirk with ROTH Capital Partners.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ROTH Capital Partnersì˜ Bill Kirkë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>William Kirk: ROTH Capital Partners, LLC, Research Division On the balance sheet, I see the $1 million in digital assets. I guess, were those investments you made? Or was it crypto that came in from customer payments? And then taking a step back on the topic, I guess, which coins, tokens, currencies do you prefer? And what are your cash allocation plans to the strategy given your cash generation and your equity issuance history?</td><td>**William Kirk:** ëŒ€ì°¨ëŒ€ì¡°í‘œì—ì„œ 100ë§Œ ë‹¬ëŸ¬ì˜ ë””ì§€í„¸ ìì‚°ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ íšŒì‚¬ê°€ ì§ì ‘ íˆ¬ìí•œ ê²ƒì¸ì§€, ì•„ë‹ˆë©´ ê³ ê° ê²°ì œë¡œ ë“¤ì–´ì˜¨ ì•”í˜¸í™”íì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ ì£¼ì œì—ì„œ í•œ ë°œ ë¬¼ëŸ¬ì„œì„œ ë³´ë©´, ì–´ë–¤ ì½”ì¸ì´ë‚˜ í† í°, í†µí™”ë¥¼ ì„ í˜¸í•˜ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  í˜„ê¸ˆ ì°½ì¶œ ëŠ¥ë ¥ê³¼ ì§€ë¶„ ë°œí–‰ ì´ë ¥ì„ ê³ ë ¤í•  ë•Œ ì´ ì „ëµì— ëŒ€í•œ í˜„ê¸ˆ ë°°ë¶„ ê³„íšì€ ì–´ë–»ê²Œ ë˜ëŠ”ì§€ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Irwin Simon: President, CEO & Chairman So that is acquisition of a Bitcoin that we acquired 3, 4 months ago. And with that, I'm going to let Lloyd Brathwaite just take you through some of our strategies that we're looking at from Bitcoin today as we see relevance with our current investors. Our current users are also Bitcoin users, and we see opportunities, as I've said in previous -- as I said in previous meetings and previous releases that we see opportunities with Bitcoin in purchasing our products, in purchasing our beer products and we see opportunities with our current investors. Lloyd?</td><td>**Irwin Simon:** 3-4ê°œì›” ì „ì— ì¸ìˆ˜í•œ ë¹„íŠ¸ì½”ì¸ ê´€ë ¨ ë‚´ìš©ì…ë‹ˆë‹¤. ì´ì œ Lloyd Brathwaiteê°€ í˜„ì¬ íˆ¬ììë“¤ê³¼ì˜ ì—°ê´€ì„±ì„ ê³ ë ¤í•œ ë¹„íŠ¸ì½”ì¸ ì „ëµì— ëŒ€í•´ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ ì‚¬ìš©ìë“¤ë„ ë¹„íŠ¸ì½”ì¸ ì‚¬ìš©ìë“¤ì´ê³ , ì´ì „ íšŒì˜ì™€ ë°œí‘œì—ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ë¹„íŠ¸ì½”ì¸ì„ í†µí•´ ìš°ë¦¬ ì œí’ˆ êµ¬ë§¤, ë§¥ì£¼ ì œí’ˆ êµ¬ë§¤ì—ì„œ ê¸°íšŒë¥¼ ë³´ê³  ìˆìœ¼ë©°, í˜„ì¬ íˆ¬ììë“¤ê³¼ë„ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. Lloyd?</td></tr>
<tr><td>Chief Information Officer: Hi, everyone. So yes, we actually invested in Bitcoin, and we're also looking at some other assets such as Ethereum and Solana. One of the things part of our strategy that's core is enabling our websites so that we can actually accept Bitcoin. So that's going to be part of our strategy later this year. Additionally, we're looking at some investment opportunities from a marketing perspective as well as looking at tokenizing potentially some stock.</td><td>**Chief Information Officer:** ì•ˆë…•í•˜ì„¸ìš”. ë„¤, ì €í¬ëŠ” ì‹¤ì œë¡œ ë¹„íŠ¸ì½”ì¸ì— íˆ¬ìí–ˆê³ , ì´ë”ë¦¬ì›€ê³¼ ì†”ë¼ë‚˜ ê°™ì€ ë‹¤ë¥¸ ìì‚°ë“¤ë„ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ í•µì‹¬ ì „ëµ ì¤‘ í•˜ë‚˜ëŠ” ì›¹ì‚¬ì´íŠ¸ì—ì„œ ì‹¤ì œë¡œ ë¹„íŠ¸ì½”ì¸ì„ ê²°ì œ ìˆ˜ë‹¨ìœ¼ë¡œ ë°›ì„ ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì˜¬í•´ í›„ë°˜ê¸° ì „ëµì˜ ì¼ë¶€ê°€ ë  ì˜ˆì •ì…ë‹ˆë‹¤. ë˜í•œ ë§ˆì¼€íŒ… ê´€ì ì—ì„œì˜ íˆ¬ì ê¸°íšŒë“¤ì„ ì‚´í´ë³´ê³  ìˆìœ¼ë©°, ì¼ë¶€ ì£¼ì‹ì˜ í† í°í™” ê°€ëŠ¥ì„±ë„ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Irwin Simon: President, CEO & Chairman And with that, I just want to make sure, listen, we're -- we see the opportunities, we see the synergies with our products, with our investors, and we're not becoming that crypto company out there, but we see tremendous synergies as we expand Tilray into many new markets and many opportunities from that. And we're working with a lot of partners out there and making sure we have the right people that understand crypto and how to do it.</td><td>**Irwin Simon:** ì´ ì ì„ í™•ì‹¤íˆ ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ë°, ì €í¬ëŠ” ê¸°íšŒë¥¼ ë³´ê³  ìˆê³ , ì €í¬ ì œí’ˆê³¼ íˆ¬ììë“¤ê³¼ì˜ ì‹œë„ˆì§€ë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ê·¸ì € ì•”í˜¸í™”í íšŒì‚¬ê°€ ë˜ë ¤ëŠ” ê²ƒì€ ì•„ë‹ˆì§€ë§Œ, Tilrayë¥¼ ì—¬ëŸ¬ ìƒˆë¡œìš´ ì‹œì¥ê³¼ ê¸°íšŒë¡œ í™•ì¥í•´ ë‚˜ê°€ë©´ì„œ ì—„ì²­ë‚œ ì‹œë„ˆì§€ë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. <br><br>í˜„ì¬ ë§ì€ íŒŒíŠ¸ë„ˆë“¤ê³¼ í˜‘ë ¥í•˜ê³  ìˆìœ¼ë©°, ì•”í˜¸í™”íë¥¼ ì´í•´í•˜ê³  ì–´ë–»ê²Œ ë‹¤ë¤„ì•¼ í•˜ëŠ”ì§€ ì•„ëŠ” ì í•©í•œ ì¸ì¬ë“¤ì„ í™•ë³´í•˜ëŠ” ë° ì£¼ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>William Kirk: ROTH Capital Partners, LLC, Research Division And going back to Germany and Europe. I guess when you're servicing those markets, how much of the product has grown today in Portugal? How much is coming from your Broken Coast GMP facility in Canada? And how much that ends up in being sold in Germany and Europe is coming from a non-GMP facility of yours in Canada? And then I guess the bigger question, what are the risks that Germany changes the way they treat product conversion or product coming from Portugal?</td><td>**William Kirk:** ROTH Capital Partnersì—ì„œ ë…ì¼ê³¼ ìœ ëŸ½ ì‹œì¥ìœ¼ë¡œ ë‹¤ì‹œ ëŒì•„ê°€ì„œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í˜„ì¬ í•´ë‹¹ ì‹œì¥ë“¤ì— ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•  ë•Œ, í¬ë¥´íˆ¬ê°ˆì—ì„œ ì¬ë°°ëœ ì œí’ˆì´ ì–¼ë§ˆë‚˜ ë˜ëŠ”ì§€ìš”? ìºë‚˜ë‹¤ì˜ Broken Coast GMP ì‹œì„¤ì—ì„œ ì˜¤ëŠ” ì œí’ˆì€ ì–¼ë§ˆë‚˜ ë˜ê³ ìš”? ê·¸ë¦¬ê³  ë…ì¼ê³¼ ìœ ëŸ½ì—ì„œ íŒë§¤ë˜ëŠ” ì œí’ˆ ì¤‘ ìºë‚˜ë‹¤ì˜ ë¹„GMP ì‹œì„¤ì—ì„œ ì˜¤ëŠ” ì œí’ˆì€ ì–¼ë§ˆë‚˜ ë˜ë‚˜ìš”? ë” í° ì§ˆë¬¸ì€, ë…ì¼ì´ í¬ë¥´íˆ¬ê°ˆì—ì„œ ì˜¤ëŠ” ì œí’ˆ ì „í™˜ì´ë‚˜ ì œí’ˆì— ëŒ€í•œ ì²˜ë¦¬ ë°©ì‹ì„ ë³€ê²½í•  ìœ„í—˜ì„±ì€ ì–´ëŠ ì •ë„ì¸ê°€ìš”?</td></tr>
<tr><td>Irwin Simon: President, CEO & Chairman So listen, number one, the majority of our product today that is sold in Europe is coming from our facilities in Europe, okay? And when product does come from Canada, it goes into Portugal, it then goes to an EU GMP certified facility. So everything sold there is EU GMP certified, okay? With that, again, there's lots of possibilities. We do have a good-sized German facility that can grow cannabis. We're one of the few, and I'm not sure why in the EU, that Germany would not allow European products to be shipped into the German marketplace. So that ultimately is something we're continuously talking to the German government about. And if they did that, there's not enough grow in German market today to be able to supply the market. So it's something that it'd be very difficult if the German authorities change the market -- change the way products come into Germany.</td><td>**Irwin Simon:** ë¨¼ì € ë§ì”€ë“œë¦¬ë©´, í˜„ì¬ ìœ ëŸ½ì—ì„œ íŒë§¤ë˜ëŠ” ì €í¬ ì œí’ˆì˜ ëŒ€ë¶€ë¶„ì€ ìœ ëŸ½ ë‚´ ì‹œì„¤ì—ì„œ ìƒì‚°ë˜ê³  ìˆìŠµë‹ˆë‹¤. ìºë‚˜ë‹¤ì—ì„œ ì œí’ˆì´ ë“¤ì–´ì˜¬ ë•ŒëŠ” í¬ë¥´íˆ¬ê°ˆì„ ê±°ì³ EU GMP ì¸ì¦ ì‹œì„¤ë¡œ ë³´ë‚´ì§‘ë‹ˆë‹¤. ë”°ë¼ì„œ ê·¸ê³³ì—ì„œ íŒë§¤ë˜ëŠ” ëª¨ë“  ì œí’ˆì€ EU GMP ì¸ì¦ì„ ë°›ì€ ê²ƒì…ë‹ˆë‹¤.<br><br>ì´ì™€ ê´€ë ¨í•´ì„œ ë‹¤ì–‘í•œ ê°€ëŠ¥ì„±ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ëŒ€ë§ˆì´ˆë¥¼ ì¬ë°°í•  ìˆ˜ ìˆëŠ” ìƒë‹¹í•œ ê·œëª¨ì˜ ë…ì¼ ì‹œì„¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. EUì—ì„œ ëª‡ ì•ˆ ë˜ëŠ” ì—…ì²´ ì¤‘ í•˜ë‚˜ì£ . ë…ì¼ì´ ì™œ ìœ ëŸ½ì‚° ì œí’ˆì˜ ë…ì¼ ì‹œì¥ ë°˜ì…ì„ í—ˆìš©í•˜ì§€ ì•ŠëŠ”ì§€ ì´í•´ê°€ ì•ˆ ë©ë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ ë…ì¼ ì •ë¶€ì™€ ì§€ì†ì ìœ¼ë¡œ ë…¼ì˜í•˜ê³  ìˆëŠ” ì‚¬ì•ˆì…ë‹ˆë‹¤. ë§Œì•½ ê·¸ë“¤ì´ í—ˆìš©í•œë‹¤ë©´, í˜„ì¬ ë…ì¼ ì‹œì¥ ë‚´ ì¬ë°°ëŸ‰ìœ¼ë¡œëŠ” ì‹œì¥ ìˆ˜ìš”ë¥¼ ì¶©ì¡±í•  ìˆ˜ ì—†ëŠ” ìƒí™©ì…ë‹ˆë‹¤. ë…ì¼ ë‹¹êµ­ì´ ì‹œì¥ì„ ë³€ê²½í•˜ê±°ë‚˜ ì œí’ˆì´ ë…ì¼ë¡œ ë“¤ì–´ì˜¤ëŠ” ë°©ì‹ì„ ë°”ê¾¼ë‹¤ë©´ ë§¤ìš° ì–´ë ¤ìš´ ìƒí™©ì´ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from the line of Robert Moskow with TD Cowen.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ TD Cowenì˜ Robert Moskowë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Xin Ma: TD Cowen, Research Division This is Victor on for Rob Moskow. Two questions for me, please. First, can you give us a state [indiscernible] for the Canadian adult-use market. Curious on your thoughts on market maturity and your pricing power in the context of the [ 12% ] growth you saw this quarter. How much of that maybe looks like volume versus price?</td><td>**Xin Ma:** TD Cowen ë¦¬ì„œì¹˜ ë””ë¹„ì „ì—ì„œ Rob Moskowë¥¼ ëŒ€ì‹ í•´ Victorì…ë‹ˆë‹¤. ë‘ ê°€ì§€ ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ë¨¼ì € ìºë‚˜ë‹¤ ì„±ì¸ìš© ì‹œì¥ì˜ í˜„í™©ì„ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ì‹œì¥ ì„±ìˆ™ë„ì™€ ì´ë²ˆ ë¶„ê¸° 12% ì„±ì¥ì„ ê³ ë ¤í–ˆì„ ë•Œ ê°€ê²© ê²°ì •ë ¥ì— ëŒ€í•œ ê²¬í•´ê°€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ ì„±ì¥ ì¤‘ì—ì„œ ë¬¼ëŸ‰ ëŒ€ë¹„ ê°€ê²©ì´ ì°¨ì§€í•˜ëŠ” ë¹„ì¤‘ì€ ì–´ëŠ ì •ë„ë¡œ ë³´ì‹œë‚˜ìš”?</td></tr>
<tr><td>William Kirk: ROTH Capital Partners, LLC, Research Division Blair, you're on the line. Blair NacNeil, Head of our Canadian market. Blair, do you want to jump in and take that and I can add to it?</td><td>**William Kirk:** ROTH Capital Partners, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸ì˜ Blairì…ë‹ˆë‹¤. ìºë‚˜ë‹¤ ì‹œì¥ ë‹´ë‹¹ ì±…ì„ìì¸ Blair NacNeilì´ ì—°ê²°ë˜ì–´ ìˆìŠµë‹ˆë‹¤. Blair, ë¨¼ì € ë‹µë³€í•´ ì£¼ì‹œê³  ì œê°€ ë³´ì¶©í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Blair MacNeil: President of Tilray Canada Yes, absolutely. Thanks, everyone. Yes, so in the quarter, we saw overall market pricing down 1.3% and volume was up 6.5%. For us, our pricing was actually up 2%, and our volume was ahead of the market. So it was a really strong quarter for us, both on the pricing side and on the volume side. As you saw, we were the only LP in the top 5 to grow share in the quarter. So very, very strong results. In terms of market maturity, what I would tell you is, in the current regulatory environment, yes, volume has slowed in terms of growth rate, but still very healthy growth rates in the market. And I think what you'll see is over the next few quarters is that -- and Irwin kind of referenced this, is that you will see the regulatory environment improve, and I think you'll see growth continue to go. Overall household penetration on cannabis in Canada is still at a very low number. So we see tremendous runway for growth in Canada within the regulatory framework.</td><td>**Blair MacNeil:** ë„¤, ë¬¼ë¡ ì…ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì— ì „ì²´ ì‹œì¥ ê°€ê²©ì€ 1.3% í•˜ë½í–ˆê³  ë¬¼ëŸ‰ì€ 6.5% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì €í¬ì˜ ê²½ìš° ê°€ê²©ì€ ì‹¤ì œë¡œ 2% ìƒìŠ¹í–ˆê³ , ë¬¼ëŸ‰ë„ ì‹œì¥ì„ ì•ì„°ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê°€ê²© ì¸¡ë©´ê³¼ ë¬¼ëŸ‰ ì¸¡ë©´ ëª¨ë‘ì—ì„œ ì •ë§ ê°•ë ¥í•œ ë¶„ê¸°ì˜€ìŠµë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” ìƒìœ„ 5ê°œ LP ì¤‘ì—ì„œ ì´ë²ˆ ë¶„ê¸°ì— ì ìœ ìœ¨ì„ ëŠ˜ë¦° ìœ ì¼í•œ íšŒì‚¬ì˜€ìŠµë‹ˆë‹¤. ì •ë§ ë§¤ìš° ê°•ë ¥í•œ ê²°ê³¼ì…ë‹ˆë‹¤.<br><br>ì‹œì¥ ì„±ìˆ™ë„ ì¸¡ë©´ì—ì„œ ë§ì”€ë“œë¦¬ë©´, í˜„ì¬ ê·œì œ í™˜ê²½ì—ì„œëŠ” ë¬¼ëŸ‰ ì„±ì¥ë¥ ì´ ë‘”í™”ëœ ê²ƒì€ ë§ì§€ë§Œ, ì—¬ì „íˆ ì‹œì¥ì—ì„œëŠ” ë§¤ìš° ê±´ì „í•œ ì„±ì¥ë¥ ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ëª‡ ë¶„ê¸°ì— ê±¸ì³ ë³´ì‹œê²Œ ë  ê²ƒì€ - ì–´ìœˆì´ ì–¸ê¸‰í–ˆë“¯ì´ - ê·œì œ í™˜ê²½ì´ ê°œì„ ë˜ëŠ” ëª¨ìŠµì„ ë³´ê²Œ ë˜ì‹¤ ê²ƒì´ê³ , ì„±ì¥ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ìºë‚˜ë‹¤ì˜ ì „ì²´ ê°€êµ¬ ëŒ€ë¹„ ëŒ€ë§ˆì´ˆ ì¹¨íˆ¬ìœ¨ì€ ì—¬ì „íˆ ë§¤ìš° ë‚®ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ê·œì œ í”„ë ˆì„ì›Œí¬ ë‚´ì—ì„œ ìºë‚˜ë‹¤ ì‹œì¥ì˜ ì—„ì²­ë‚œ ì„±ì¥ ì—¬ë ¥ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤.</td></tr>
<tr><td>Irwin Simon: President, CEO & Chairman I think I'll jump -- just jump on that for a second. The Canadian market was the first. And as we go into our sixth year, with that, again, from a regulatory standpoint, and what are we still sitting with, we're still sitting with a high excise tax. We're still sitting with lots of regulation. We've been through price compression. We've been through COVID. We've been through an illicit market. We've been through over 1,800 LPs that are out there, a lot of them have gone away, a lot of growth facilities. And we've gone through educating the Canadian consumer on the benefits of cannabis, and the legality of cannabis without in actuality being able to advertise. And we have built our good supply today, Blair, which is at retail about a $250 million brand.</td><td>**Irwin Simon:** ì ê¹ ì œê°€ ë‹µë³€ì„ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìºë‚˜ë‹¤ ì‹œì¥ì´ ì²« ë²ˆì§¸ì˜€ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  6ë…„ì°¨ì— ì ‘ì–´ë“¤ë©´ì„œ, ê·œì œ ê´€ì ì—ì„œ ë³´ë©´ ì—¬ì „íˆ ë†’ì€ ì†Œë¹„ì„¸ë¥¼ ì•ˆê³  ìˆìŠµë‹ˆë‹¤. ì—¬ì „íˆ ë§ì€ ê·œì œê°€ ìˆê³ ìš”. ê°€ê²© ì••ë°•ì„ ê²ªì—ˆê³ , ì½”ë¡œë‚˜ë„ ê²ªì—ˆìŠµë‹ˆë‹¤. ë¶ˆë²• ì‹œì¥ë„ ìˆì—ˆê³ , 1,800ê°œê°€ ë„˜ëŠ” ë¼ì´ì„ ìŠ¤ ìƒì‚°ì—…ì²´(LP)ë“¤ì´ ìˆì—ˆëŠ”ë°, ê·¸ ì¤‘ ë§ì€ ì—…ì²´ë“¤ì´ ì‚¬ë¼ì¡Œê³  ë§ì€ ì¬ë°° ì‹œì„¤ë“¤ë„ ë§ˆì°¬ê°€ì§€ì˜€ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹¤ì œë¡œëŠ” ê´‘ê³ ë¥¼ í•  ìˆ˜ ì—†ëŠ” ìƒí™©ì—ì„œ ìºë‚˜ë‹¤ ì†Œë¹„ìë“¤ì—ê²Œ ëŒ€ë§ˆì´ˆì˜ íš¨ëŠ¥ê³¼ í•©ë²•ì„±ì— ëŒ€í•´ êµìœ¡í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ë‚  ìš°ë¦¬ëŠ” Good Supplyë¥¼ êµ¬ì¶•í–ˆëŠ”ë°, Blair, ì´ëŠ” ì†Œë§¤ ê¸°ì¤€ìœ¼ë¡œ ì•½ 2ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ ê·œëª¨ì˜ ë¸Œëœë“œì…ë‹ˆë‹¤.</td></tr>
<tr><td>Blair MacNeil: President of Tilray Canada</td><td>**Blair MacNeil:** I notice you've only provided "President of Tilray Canada" which appears to be a title or speaker identification rather than spoken content from an earnings call Q&A session.<br><br>Could you please provide the actual management response or spoken content that you'd like me to translate into Korean? I'm ready to translate the substantive remarks once you share them.</td></tr>
<tr><td>Irwin Simon: President, CEO & Chairman And from that, that's what we've built over the last 5, 6 years. We have over 5 million square feet to grow. We have the largest growth facility in Canada with 237 metric tons and maybe even more. So the Canadian market has been a great pivotal point for us. Now what we're hoping for is on excise tax, there are some concessions. We're hoping that the Canadian provincial governments allow us to sell our drinks into other retail outlets like restaurants that need help or independent retailers or liquor stores. We're looking for changes in regards to where medical cannabis is sold, where it's sold directly through drugstores. And that would change a lot for our Canadian market. So we look now for some big opportunities coming to the Canadian market. And Blair and his team have really put us in a good space there to really move beyond and a good grow in regards to our products.</td><td>**Irwin Simon:** ê·¸ë¦¬ê³  ê·¸ê²ƒì„ ë°”íƒ•ìœ¼ë¡œ ì§€ë‚œ 5-6ë…„ê°„ ìš°ë¦¬ê°€ êµ¬ì¶•í•´ì˜¨ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì„±ì¥í•  ìˆ˜ ìˆëŠ” 500ë§Œ í‰ë°©í”¼íŠ¸ ì´ìƒì˜ ê³µê°„ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. 237ë¯¸í„°í†¤, ì–´ì©Œë©´ ê·¸ë³´ë‹¤ ë” ë§ì€ ìƒì‚°ëŠ¥ë ¥ì„ ê°–ì¶˜ ìºë‚˜ë‹¤ ìµœëŒ€ ê·œëª¨ì˜ ì„±ì¥ ì‹œì„¤ì„ ìš´ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìºë‚˜ë‹¤ ì‹œì¥ì€ ìš°ë¦¬ì—ê²Œ í›Œë¥­í•œ ì „í™˜ì ì´ ë˜ì–´ì™”ìŠµë‹ˆë‹¤.<br><br>ì´ì œ ìš°ë¦¬ê°€ ê¸°ëŒ€í•˜ê³  ìˆëŠ” ê²ƒì€ ì†Œë¹„ì„¸(excise tax)ì— ëŒ€í•œ ì¼ë¶€ ì–‘ë³´ì…ë‹ˆë‹¤. ìºë‚˜ë‹¤ ì£¼ì •ë¶€ë“¤ì´ ìš°ë¦¬ ìŒë£Œ ì œí’ˆì„ ë„ì›€ì´ í•„ìš”í•œ ë ˆìŠ¤í† ë‘ì´ë‚˜ ë…ë¦½ ì†Œë§¤ì , ì£¼ë¥˜ íŒë§¤ì  ê°™ì€ ë‹¤ë¥¸ ì†Œë§¤ ì±„ë„ì—ì„œë„ íŒë§¤í•  ìˆ˜ ìˆë„ë¡ í—ˆìš©í•´ì£¼ê¸°ë¥¼ í¬ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ë£Œìš© ëŒ€ë§ˆì´ˆê°€ íŒë§¤ë˜ëŠ” ê³³, ì¦‰ ì•½êµ­ì„ í†µí•´ ì§ì ‘ íŒë§¤ë˜ëŠ” ë°©ì‹ì— ëŒ€í•œ ë³€í™”ë„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ° ë³€í™”ë“¤ì´ ìš°ë¦¬ ìºë‚˜ë‹¤ ì‹œì¥ì— í° ë³€í™”ë¥¼ ê°€ì ¸ë‹¤ì¤„ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì´ì œ ìºë‚˜ë‹¤ ì‹œì¥ì— ë‹¤ê°€ì˜¬ í° ê¸°íšŒë“¤ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¸”ë ˆì–´ì™€ ê·¸ì˜ íŒ€ì´ ì •ë§ ìš°ë¦¬ë¥¼ ì¢‹ì€ ìœ„ì¹˜ì— ì˜¬ë ¤ë†“ì•˜ê³ , ì´ë¥¼ ë°”íƒ•ìœ¼ë¡œ ì œí’ˆ ë¶€ë¬¸ì—ì„œ ë” ë‚˜ì•„ê°€ ì¢‹ì€ ì„±ì¥ì„ ì´ë£° ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Xin Ma: TD Cowen, Research Division Got it. And then my second question is, so beverage gross margin was about 50 bps lighter than kind of we expected. Can you remind us of your plan on improving profitability in that segment? And also, where are you on that path, that 420 path? And what still needs to be done?</td><td>**Xin Ma:** ìŒë£Œ ë¶€ë¬¸ ì´ë§ˆì§„ì´ ì €í¬ê°€ ì˜ˆìƒí–ˆë˜ ê²ƒë³´ë‹¤ ì•½ 50bp ì •ë„ ë‚®ì•˜ìŠµë‹ˆë‹¤. í•´ë‹¹ ë¶€ë¬¸ì˜ ìˆ˜ìµì„± ê°œì„  ê³„íšì„ ë‹¤ì‹œ í•œë²ˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  420 ê²½ë¡œì—ì„œ í˜„ì¬ ì–´ëŠ ë‹¨ê³„ì— ìˆëŠ”ì§€, ê·¸ë¦¬ê³  ì•„ì§ í•´ì•¼ í•  ì¼ë“¤ì´ ë¬´ì—‡ì¸ì§€ë„ ì•Œë ¤ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Irwin Simon: President, CEO & Chairman So as you saw, we've taken $25 million of cost out, I mean, there's more to go. We've gone through and I think SKU rationalization, $20 million of SKU rationalization and there's more to go. We've closed three facilities so far. So come back in acquisitions, we have acquired close to 12 -- we closed 12 brands. We have closed -- we had 10 facilities. We've had 18 brewpubs, and also, we have over 900-plus distributors out there. So bringing this all together under one management, one infrastructure, and we're seeing progress, but there's a lot of wood to chop there yet to get those margins to where we need to do. And whether it's the procurement of cans, the procurement of hops, and one of the biggest things, which you heard me mention in my remarks, a lot of these brands, as we were buying them and decisions were made by the previous owners, we were delisted in a lot of retailers out there. So with that, you saw major declines in these businesses, and we missed the windows of getting these products in the stores. Now these windows have opened up, and getting these products now relisted in these retailers is something that we've been doing. And that's why whether it's Shock Top, whether it's Redhook, whether it's some of our other brands you're seeing the growth there. And that's what's going to happen to get our gross margins up here. And listen, let's all face it, the beer category is not one of the easiest categories out there right now. And we're fighting through it, both on growth side, innovation side. And I've said it from the beginning, how do I make beer fun again. And that's something we're trying to do. Along the way, make money with it too.</td><td>**Irwin Simon:** ë³´ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” 2,500ë§Œ ë‹¬ëŸ¬ì˜ ë¹„ìš©ì„ ì ˆê°í–ˆê³ , ì•„ì§ ë” í•  ì¼ì´ ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. SKU í•©ë¦¬í™”ë¥¼ í†µí•´ 2,000ë§Œ ë‹¬ëŸ¬ë¥¼ ì ˆì•½í–ˆëŠ”ë° ì´ ë¶€ë¶„ë„ ë” ì§„í–‰í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ 3ê°œ ì‹œì„¤ì„ íì‡„í–ˆìŠµë‹ˆë‹¤. <br><br>ì¸ìˆ˜í•©ë³‘ì„ ëŒì•„ë³´ë©´, ì €í¬ëŠ” ê±°ì˜ 12ê°œ... 12ê°œ ë¸Œëœë“œë¥¼ ì¸ìˆ˜í–ˆìŠµë‹ˆë‹¤. 10ê°œ ì‹œì„¤ì„ íì‡„í–ˆê³ , 18ê°œì˜ ë¸Œë£¨íì„ ìš´ì˜í•˜ê³  ìˆìœ¼ë©°, 900ê°œê°€ ë„˜ëŠ” ìœ í†µì—…ì²´ë“¤ê³¼ í•¨ê»˜ ì¼í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì„ í•˜ë‚˜ì˜ ê²½ì˜ì§„, í•˜ë‚˜ì˜ ì¸í”„ë¼ í•˜ì— í†µí•©í•˜ëŠ” ê³¼ì •ì—ì„œ ì§„ì „ì„ ë³´ì´ê³  ìˆì§€ë§Œ, ë§ˆì§„ì„ í•„ìš”í•œ ìˆ˜ì¤€ê¹Œì§€ ëŒì–´ì˜¬ë¦¬ê¸° ìœ„í•´ì„œëŠ” ì•„ì§ í•´ì•¼ í•  ì¼ì´ ë§ì´ ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. ìº” ì¡°ë‹¬ì´ë“  í™‰ ì¡°ë‹¬ì´ë“ , ê·¸ë¦¬ê³  ì œê°€ ë°œì–¸ì—ì„œ ì–¸ê¸‰í–ˆë˜ ê°€ì¥ í° ìš”ì†Œ ì¤‘ í•˜ë‚˜ì¸ë°, ì´ëŸ° ë¸Œëœë“œë“¤ì„ ì¸ìˆ˜í•  ë‹¹ì‹œ ì´ì „ ì†Œìœ ì£¼ë“¤ì´ ë‚´ë¦° ê²°ì •ë“¤ë¡œ ì¸í•´ ë§ì€ ì†Œë§¤ì—…ì²´ì—ì„œ ì €í¬ ì œí’ˆì´ íŒë§¤ ì¤‘ë‹¨ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼ ì´ë“¤ ì‚¬ì—…ì—ì„œ í° ë§¤ì¶œ ê°ì†Œë¥¼ ê²ªì—ˆê³ , ë§¤ì¥ì— ì œí’ˆì„ ì…ì ì‹œí‚¬ ê¸°íšŒë¥¼ ë†“ì³¤ìŠµë‹ˆë‹¤. <br><br>ì´ì œ ê·¸ëŸ° ê¸°íšŒë“¤ì´ ë‹¤ì‹œ ì—´ë¦¬ê³  ìˆê³ , ì´ëŸ° ì†Œë§¤ì—…ì²´ë“¤ì— ì œí’ˆì„ ì¬ì…ì ì‹œí‚¤ëŠ” ì‘ì—…ì„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ Shock Topì´ë“  Redhookì´ë“  ì €í¬ ë‹¤ë¥¸ ë¸Œëœë“œë“¤ì—ì„œ ì„±ì¥ì„ ë³´ê³  ê³„ì‹  ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì €í¬ ì´ì´ìµë¥ ì„ ëŒì–´ì˜¬ë¦¬ëŠ” ë°©ë²•ì…ë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ë§¥ì£¼ ì¹´í…Œê³ ë¦¬ëŠ” í˜„ì¬ ê°€ì¥ ì‰¬ìš´ ì¹´í…Œê³ ë¦¬ê°€ ì•„ë‹™ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì„±ì¥ ì¸¡ë©´ì—ì„œë“  í˜ì‹  ì¸¡ë©´ì—ì„œë“  ì´ë¥¼ ê·¹ë³µí•˜ê¸° ìœ„í•´ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì²˜ìŒë¶€í„° ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì–´ë–»ê²Œ í•˜ë©´ ë§¥ì£¼ë¥¼ ë‹¤ì‹œ ì¬ë¯¸ìˆê²Œ ë§Œë“¤ ìˆ˜ ìˆì„ê¹Œê°€ í•µì‹¬ì…ë‹ˆë‹¤. ê·¸ê²ƒì´ ìš°ë¦¬ê°€ ì‹œë„í•˜ê³  ìˆëŠ” ì¼ì´ì£ . ê·¸ ê³¼ì •ì—ì„œ ìˆ˜ìµë„ ì°½ì¶œí•´ì•¼ í•˜ê³ ìš”.</td></tr>
<tr><td>Operator: Ladies and gentlemen, our final question comes from the line of Frederico Gomes with ATB Capital Markets.</td><td>**Operator:** ì‹ ì‚¬ ìˆ™ë…€ ì—¬ëŸ¬ë¶„, ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ ATB Capital Marketsì˜ Frederico Gomesë‹˜ìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Frederico Yokota Gomes: ATB Capital Markets Inc., Research Division First question, just thinking about the issues in Portugal. I'm curious how do you see that in terms of managing future risk in terms of your international strategy, whether you're taking steps to diversify your supply chain there? And how would you go about doing that?</td><td>**Frederico Yokota Gomes:** í¬ë¥´íˆ¬ê°ˆì—ì„œ ë°œìƒí•œ ë¬¸ì œë“¤ì— ëŒ€í•´ ì²« ë²ˆì§¸ ì§ˆë¬¸ì„ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. êµ­ì œ ì „ëµ ì¸¡ë©´ì—ì„œ í–¥í›„ ë¦¬ìŠ¤í¬ ê´€ë¦¬ë¥¼ ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  í˜„ì§€ ê³µê¸‰ë§ ë‹¤ê°í™”ë¥¼ ìœ„í•œ ì¡°ì¹˜ë¥¼ ì·¨í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë§Œì•½ ê·¸ë ‡ë‹¤ë©´ ì–´ë–¤ ë°©ì‹ìœ¼ë¡œ ì§„í–‰í•˜ì‹¤ ê³„íšì¸ê°€ìš”?</td></tr>
<tr><td>Irwin Simon: President, CEO & Chairman So number one, we've got 1.5 million square foot facility in Portugal. We're not picking up and moving it, okay? I mean over a couple of hundred million dollars of built and it's a state-of-the-art facility. So I'm in Portugal, I got to stay there. So I got to figure out how to work within those confinements. And I must tell you, I've had some great meetings with two Ministers in Portugal at the highest levels, and they're very open. There's a new government in Portugal, and they want business. They don't want us leaving. They want to build upon our business there, and they've been very, very supportive of working with us. And since my meetings with our people, we've seen lots of changes and been getting our permits. So I feel good. On the other hand, listen, we do have a facility in Germany, nowhere near what we have in Portugal. We do have the ability to ship from Canada, and where we would ship it directly into the U.K. and directly into other markets to ensure EU GMP. So we have options. But first and foremost, we are far from giving up on the Portuguese market.</td><td>**Irwin Simon:** ì²« ë²ˆì§¸ë¡œ, í¬ë¥´íˆ¬ê°ˆì— 150ë§Œ í‰ë°©í”¼íŠ¸ ê·œëª¨ì˜ ì‹œì„¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê±¸ ë“¤ì–´ì„œ ì˜®ê¸¸ ìˆ˜ëŠ” ì—†ì£ . ê±´ì„¤ì—ë§Œ ìˆ˜ì–µ ë‹¬ëŸ¬ê°€ íˆ¬ì…ëœ ìµœì²¨ë‹¨ ì‹œì„¤ì…ë‹ˆë‹¤. í¬ë¥´íˆ¬ê°ˆì— ìˆëŠ” ì´ìƒ ê±°ê¸° ë¨¸ë¬¼ëŸ¬ì•¼ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ ì œì•½ ì¡°ê±´ ì•ˆì—ì„œ ì–´ë–»ê²Œ ìš´ì˜í• ì§€ ë°©ë²•ì„ ì°¾ì•„ì•¼ í•˜ëŠ” ìƒí™©ì…ë‹ˆë‹¤.<br><br>ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€, í¬ë¥´íˆ¬ê°ˆ ìµœê³ ìœ„ê¸‰ ì¥ê´€ ë‘ ë¶„ê³¼ í›Œë¥­í•œ íšŒì˜ë¥¼ ê°€ì¡Œë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë¶„ë“¤ì´ ë§¤ìš° ê°œë°©ì ì´ì—ˆì–´ìš”. í¬ë¥´íˆ¬ê°ˆì— ìƒˆ ì •ë¶€ê°€ ë“¤ì–´ì„°ëŠ”ë°, ì´ë“¤ì€ ì‚¬ì—…ì„ ì›í•©ë‹ˆë‹¤. ìš°ë¦¬ê°€ ë– ë‚˜ëŠ” ê²ƒì„ ì›í•˜ì§€ ì•Šì•„ìš”. ìš°ë¦¬ ì‚¬ì—…ì„ ë”ìš± í™•ì¥í•˜ê¸°ë¥¼ ì›í•˜ê³  ìˆìœ¼ë©°, ìš°ë¦¬ì™€ í˜‘ë ¥í•˜ëŠ” ë° ë§¤ìš° ì§€ì§€ì ì¸ ì…ì¥ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ ì§ì›ë“¤ê³¼ì˜ íšŒì˜ ì´í›„ë¡œ ë§ì€ ë³€í™”ë¥¼ ë³´ê³  ìˆê³ , í—ˆê°€ë„ ë°›ê³  ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í•œí¸, ë…ì¼ì— ì‹œì„¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. í¬ë¥´íˆ¬ê°ˆì— ìˆëŠ” ê·œëª¨ì—ëŠ” ë¯¸ì¹˜ì§€ ëª»í•˜ì§€ë§Œìš”. ë˜í•œ ìºë‚˜ë‹¤ì—ì„œ ì§ì ‘ ì˜êµ­ìœ¼ë¡œ, ê·¸ë¦¬ê³  ë‹¤ë¥¸ ì‹œì¥ìœ¼ë¡œ ì§ì ‘ ì¶œí•˜í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ë„ ê°–ì¶”ê³  ìˆì–´ì„œ EU GMPë¥¼ ë³´ì¥í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì„ íƒì§€ëŠ” ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë¬´ì—‡ë³´ë‹¤ ì¤‘ìš”í•œ ê²ƒì€, í¬ë¥´íˆ¬ê°ˆ ì‹œì¥ì„ í¬ê¸°í•˜ëŠ” ê²ƒê³¼ëŠ” ê±°ë¦¬ê°€ ë©€ë‹¤ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Frederico Yokota Gomes: ATB Capital Markets Inc., Research Division And other question here, just on Germany. Could you talk about the proposed change there in legislation in terms of prescriptions and how the market works? How do you think that could impact that market? And whether you think that draft that's going there may be approved or not as is? Or you expect changes to that draft? And in terms of timing as well, when do you think the market there could change in terms of the legislation?</td><td>**Frederico Yokota Gomes:** ë…ì¼ì— ê´€í•œ ë˜ ë‹¤ë¥¸ ì§ˆë¬¸ì…ë‹ˆë‹¤. ë…ì¼ì—ì„œ ì œì•ˆëœ ì²˜ë°©ì „ ê´€ë ¨ ë²•ì•ˆ ë³€ê²½ê³¼ ì‹œì¥ ìš´ì˜ ë°©ì‹ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ì´ê²ƒì´ í•´ë‹¹ ì‹œì¥ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ìš”? ê·¸ë¦¬ê³  í˜„ì¬ ì§„í–‰ ì¤‘ì¸ ì´ˆì•ˆì´ ê·¸ëŒ€ë¡œ ìŠ¹ì¸ë  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€, ì•„ë‹ˆë©´ ì´ˆì•ˆì— ë³€ê²½ì´ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œëŠ”ì§€ìš”? ì‹œê¸°ì ì¸ ì¸¡ë©´ì—ì„œë„, ë…ì¼ ì‹œì¥ì´ ë²•ì•ˆìœ¼ë¡œ ì¸í•´ ì–¸ì œì¯¤ ë³€í™”í•  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Irwin Simon: President, CEO & Chairman Listen, we're supportive of change. But again, I don't want to go there and speculate until I know what the change is, okay. And I think so far, the good news is what we're seeing is the continuous demand and online prescription has not been one of the biggest drivers here. So if there is change, I think patients will find other ways to go out there and purchase cannabis. And it's interesting because Germany has a strong independent drug chains out there. There's no CVS, there's no Wallgreens. Individuals are allowed to own like 6 drug stores, are all independent. So like I said, there is multiple stores out there, it's not online. So I see even if it did change and you can't buy it online, there's still the retail outlets to go to out there. And I'd like to see some of the change. There's lots of changes that we continuously talked about that didn't happen. And we, with our lobby groups are out there working with the German government on what's the right thing for the patients because this here is important, too. The difference in medical cannabis is like medicine. If you didn't give patients access to get medicine, that's a problem. If you could not your medicine and didn't have access, patients that are sick are dependent on, that's an issue. So this is being sold as medicine, from a medical standpoint, not from a recreational if you don't get your cannabis from a recreational standpoint that may not be as an issue, but you're not getting your medicine and the government has to take that into view when they're deciding what they're going to do here. Great. Let me just say this here. I know a lot of have joined now. Unfortunately, not us, there was a technical problem with our provider. And those that were online, did not hear my comments. Sorry about that, guys. You missed some great comments and Carl's comments, okay? If you want to hear me again say it, you can go online and listen, and I encourage you to do that because there's some really good information that both Carl and I delivered today. And I apologize and the carrier, they'll hear from us and definitely disappointed. I know you heard music. So we had a lot more to say than the music. But please, it has been recorded. It is online, and you'll get every bit of it. And for some reason, there's an issue, let Berrin know and we'll make sure you get it, and I'm really sorry about that. In regards to the analyst questions, I think you heard most of those. So you'll be able to get those, the analysts that were here, we're able to hear Carl in our remarks. So I apologize profusely for that. With that, thank you very much for your time today. I hope some of it wasn't wasted by not hearing our comment. But now you'll have to go online and listen to it. It's only Q1 in 2026. One of our smaller quarters. There's a lot to do. And as you can see, we have a lot of good things in place and trust me, there has been times like you look at and sort of say, what the heck are we doing here, when you look at your stock price, you look at different things. But this team in over 5 years really have brought a lot together here, in rebuilding a Canadian cannabis business basically from scratch, building facilities, building brands, building products, building different strains, genetics, new innovation and some of the new innovation that's coming out of there, building infrastructure and sales and marketing teams. And again, going through price compression, going through COVID, going through the illicit market as one of your biggest competitor out there, and I really want to commend in the Canadian team and what they've been able to do. In regards to our International Cannabis business. Same thing. It has come together basically with the acquisition of Tilray, and it is really a business that I see tremendous opportunities. And we now are getting requests in different countries, whether India, Middle East and places like that in regards to medical cannabis and the opportunities there, and there's a lot of countries and there are a lot of different countries out there that are realizing the benefits of that and also realizing the benefits of medical cannabis versus medicines and cost of drugs in that out there today, and what the benefits will be. So I see big opportunities for us today. Rajnish Ohri has joined us as new Head of Europe, and is bringing the teams together. And we've done a lot with our Canadian teams to integrate these businesses to get synergies and savings and to get a lot of the know-how because one of the things -- cannabis is agriculture. It's growing, it's yield, it's the size of the flower, it's the potency, and that is something that's important out there. And this is not an industry that -- it's an industry that's spread around the illicit market for many, many years, but it's not an industry that's been around from a legalized market. It's not an industry that's been around from a growth, from a research and development that's all coming together. And countries are realizing the opportunities and what they're doing, not allowing their citizens and patients to be able to buy these products. The other thing they're realizing is there's tax dollars, that they're missing and if tax dollars are being sold through an illicit market. In regards to rescheduling, President Trump with his different tweets and his different comments, I think, realizes that something has to happen here in rescheduling. Last week with his tweet or 2 weeks ago in regards to CBD, in regards to senior citizens, and I can't tell you how many people tell me in using CBD and THC products in regards to pain and anxiety and that and the benefits for it. What we're seeing today on our Delta-9 products and being sold in limited states and the demand for it. Again, what Blair has seen in the Canadian market with building a $40-plus million business and today, just being sold within cannabis stores. And again, at prices that are not the cheapest prices out there. So we see tremendous opportunity in the Beverage business. In regards to our Beverage business, it's work we got to do. And again, we got into it in 2020 with the acquisition of SweetWater, acquired Montauk, acquired other brands and the businesses from ABI and then the business from Molson. We got some great brands, but bringing it all together is a lot of work, bringing the facilities together, getting the cost out, getting the margins out, getting the right facilities. And that's something that Tilray is doing and the team is doing out of Atlanta to bring all this together. And as I said before, not an easy business today with changes happening, but we will be in the Beverage business, not just the beer business. And with that, there's a lot of interest in products we're working on. In regards to our Spirits business. The team is working with our distributor, RNDC. And we've really put a plan in place with RNDC to be in our major markets. Yes, the bourbon category is a tougher category today than it was, but Breckenridge Bourbon is a great tasting product out there, and there's great demand in certain markets. At the same time, our Vodka has great demand and our Gin and some of our new products that we've come out with are really, really good products and some of the first timer innovation. And last but not least, you hear me talk about our Wellness business. What Jared and team have done on Wellness where we acquired this, there was a negative EBITDA of about $5 million, $6 million and where it's turned around to today, and somebody that's been part of the Wellness category since 1992, '93 and see the growth. And it's all we talk about Wellness. Wellness and Food in regards to the Trump Administration and taking colorings out of food today, higher protein, protein, protein, protein and some of the highest protein is in hemp foods because it's a plant that's grown. So we're in a lot of different categories. We're in a lot of unique places. You look at our balance sheet in regards to our debt-to-equity. It's in a great place. We ended the quarter with $260 million of cash. So there's a lot of good things happening, but there's a lot of work to do. I really want to thank our team that really makes this happen and roll up our sleeves. Even though there's 2,500 employees around the world here, not a lot for a lot we got to get done. So with that, I want to thank everybody for listening. Please go back and re-listen to our comments. There's a lot of good comments that come out of today. Thank you to our shareholders for your support and get out there and vote as we have our AGM coming up. With that, have a great Thursday, and look forward to speaking to you in the new year with our Q2 results. Thank you.</td><td>**Irwin Simon:** ì €í¬ëŠ” ë³€í™”ë¥¼ ì§€ì§€í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì–´ë–¤ ë³€í™”ì¸ì§€ ì•Œê¸° ì „ê¹Œì§€ëŠ” ì¶”ì¸¡í•˜ê³  ì‹¶ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ê¸ˆê¹Œì§€ ì¢‹ì€ ì†Œì‹ì€ ì§€ì†ì ì¸ ìˆ˜ìš”ë¥¼ ë³´ê³  ìˆë‹¤ëŠ” ê²ƒì´ê³ , ì˜¨ë¼ì¸ ì²˜ë°©ì´ ì—¬ê¸°ì„œ ê°€ì¥ í° ë™ë ¥ ì¤‘ í•˜ë‚˜ê°€ ì•„ë‹ˆì—ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë³€í™”ê°€ ìˆë‹¤ë©´, í™˜ìë“¤ì€ ëŒ€ë§ˆì´ˆë¥¼ êµ¬ë§¤í•  ë‹¤ë¥¸ ë°©ë²•ì„ ì°¾ì„ ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>í¥ë¯¸ë¡œìš´ ì ì€ ë…ì¼ì—ëŠ” ê°•ë ¥í•œ ë…ë¦½ ì•½êµ­ ì²´ì¸ë“¤ì´ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. CVSë„ ì—†ê³  ì›”ê·¸ë¦°ìŠ¤(Walgreens)ë„ ì—†ìŠµë‹ˆë‹¤. ê°œì¸ë“¤ì´ 6ê°œ ì •ë„ì˜ ì•½êµ­ì„ ì†Œìœ í•  ìˆ˜ ìˆê³ , ëª¨ë‘ ë…ë¦½ì ì…ë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì˜¨ë¼ì¸ì´ ì•„ë‹Œ ì—¬ëŸ¬ ë§¤ì¥ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë³€í™”ê°€ ìƒê²¨ì„œ ì˜¨ë¼ì¸ìœ¼ë¡œ êµ¬ë§¤í•  ìˆ˜ ì—†ê²Œ ë˜ë”ë¼ë„, ì—¬ì „íˆ ê°ˆ ìˆ˜ ìˆëŠ” ì†Œë§¤ íŒë§¤ì ë“¤ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ì €í¬ëŠ” ë³€í™”ë¥¼ ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. ì§€ì†ì ìœ¼ë¡œ ë…¼ì˜í•´ì™”ì§€ë§Œ ì‹¤í˜„ë˜ì§€ ì•Šì€ ë§ì€ ë³€í™”ë“¤ì´ ìˆì—ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë¡œë¹„ ê·¸ë£¹ë“¤ê³¼ í•¨ê»˜ ë…ì¼ ì •ë¶€ì™€ í˜‘ë ¥í•˜ì—¬ í™˜ìë“¤ì—ê²Œ ì˜¬ë°”ë¥¸ ë°©í–¥ì´ ë¬´ì—‡ì¸ì§€ ë…¼ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì´ ë§¤ìš° ì¤‘ìš”í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. <br><br>ì˜ë£Œìš© ëŒ€ë§ˆì´ˆì˜ ì°¨ì´ì ì€ ì˜ì•½í’ˆê³¼ ê°™ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. í™˜ìë“¤ì´ ì˜ì•½í’ˆì— ì ‘ê·¼í•  ìˆ˜ ì—†ë‹¤ë©´ ë¬¸ì œê°€ ë©ë‹ˆë‹¤. ì•½ì„ êµ¬í•  ìˆ˜ ì—†ê³  ì ‘ê·¼í•  ìˆ˜ ì—†ë‹¤ë©´, ì•„í”ˆ í™˜ìë“¤ì´ ì˜ì¡´í•˜ê³  ìˆëŠ” ìƒí™©ì—ì„œ ì´ëŠ” ì‹¬ê°í•œ ë¬¸ì œì…ë‹ˆë‹¤. ì´ê²ƒì€ ì˜¤ë½ìš©ì´ ì•„ë‹Œ ì˜í•™ì  ê´€ì ì—ì„œ ì˜ì•½í’ˆìœ¼ë¡œ íŒë§¤ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¤ë½ìš© ê´€ì ì—ì„œ ëŒ€ë§ˆì´ˆë¥¼ êµ¬í•˜ì§€ ì•ŠëŠ”ë‹¤ë©´ ê·¸ê²ƒì´ ë¬¸ì œê°€ ë˜ì§€ ì•Šì„ ìˆ˜ë„ ìˆì§€ë§Œ, ì—¬ëŸ¬ë¶„ì€ ì˜ì•½í’ˆì„ êµ¬í•˜ì§€ ëª»í•˜ê³  ìˆëŠ” ê²ƒì´ê³ , ì •ë¶€ëŠ” ì—¬ê¸°ì„œ ë¬´ì—‡ì„ í• ì§€ ê²°ì •í•  ë•Œ ì´ ì ì„ ê³ ë ¤í•´ì•¼ í•©ë‹ˆë‹¤.<br><br>ì¢‹ìŠµë‹ˆë‹¤. ì—¬ê¸°ì„œ í•œ ë§ì”€ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§ì€ ë¶„ë“¤ì´ ì§€ê¸ˆ ì°¸ì—¬í•˜ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì•ˆíƒ€ê¹ê²Œë„ ì €í¬ê°€ ì•„ë‹Œ ì„œë¹„ìŠ¤ ì œê³µì—…ì²´ì— ê¸°ìˆ ì  ë¬¸ì œê°€ ìˆì—ˆìŠµë‹ˆë‹¤. ì˜¨ë¼ì¸ì— ì ‘ì†í•´ ê³„ì…¨ë˜ ë¶„ë“¤ì€ ì œ ë°œì–¸ì„ ë“£ì§€ ëª»í•˜ì…¨ìŠµë‹ˆë‹¤. ì£„ì†¡í•©ë‹ˆë‹¤. ì •ë§ í›Œë¥­í•œ ë°œì–¸ë“¤ê³¼ ì¹¼ì˜ ë°œì–¸ë“¤ì„ ë†“ì¹˜ì…¨ë„¤ìš”.<br><br>ì œ ë§ì„ ë‹¤ì‹œ ë“£ê³  ì‹¶ìœ¼ì‹œë‹¤ë©´ ì˜¨ë¼ì¸ì—ì„œ ë“¤ìœ¼ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì¹¼ê³¼ ì œê°€ ì˜¤ëŠ˜ ì „ë‹¬í•œ ì •ë§ ì¢‹ì€ ì •ë³´ë“¤ì´ ìˆê¸° ë•Œë¬¸ì— ê¼­ ë“¤ì–´ë³´ì‹œê¸¸ ê¶Œí•©ë‹ˆë‹¤. ì£„ì†¡í•©ë‹ˆë‹¤. í†µì‹ ì‚¬ì—ì„œ ì—°ë½ì„ ë°›ì„ ê²ƒì´ê³  ì •ë§ ì‹¤ë§ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. ìŒì•…ì´ ë“¤ë ¸ë‹¤ëŠ” ê±¸ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ìŒì•…ë³´ë‹¤ í›¨ì”¬ ë§ì€ ì´ì•¼ê¸°ë¥¼ í–ˆëŠ”ë° ë§ì´ì£ . í•˜ì§€ë§Œ ë…¹ìŒì´ ë˜ì—ˆê³  ì˜¨ë¼ì¸ì— ì˜¬ë¼ê°€ ìˆìœ¼ë‹ˆ ëª¨ë“  ë‚´ìš©ì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. í˜¹ì‹œ ë¬¸ì œê°€ ìˆìœ¼ì‹œë©´ ë² ë¦°ì—ê²Œ ì•Œë ¤ì£¼ì‹œë©´ í™•ì‹¤íˆ ë°›ì•„ë³´ì‹¤ ìˆ˜ ìˆë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ì •ë§ ì£„ì†¡í•©ë‹ˆë‹¤.<br><br>ì• ë„ë¦¬ìŠ¤íŠ¸ ì§ˆë¬¸ë“¤ê³¼ ê´€ë ¨í•´ì„œëŠ” ëŒ€ë¶€ë¶„ ë“¤ìœ¼ì…¨ì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ ë¶€ë¶„ë“¤ì€ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆì„ ê²ë‹ˆë‹¤. í˜„ì¥ì— ìˆë˜ ì• ë„ë¦¬ìŠ¤íŠ¸ë“¤ì€ ì¹¼ì˜ ë°œì–¸ê³¼ ì €í¬ ì½”ë©˜íŠ¸ë¥¼ ë“¤ì„ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ ì ì— ëŒ€í•´ ì§„ì‹¬ìœ¼ë¡œ ì‚¬ê³¼ë“œë¦½ë‹ˆë‹¤.<br><br>ì˜¤ëŠ˜ ì‹œê°„ì„ ë‚´ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì €í¬ ì½”ë©˜íŠ¸ë¥¼ ë“£ì§€ ëª»í•´ì„œ ì‹œê°„ì´ ë‚­ë¹„ë˜ì§€ ì•Šì•˜ê¸°ë¥¼ ë°”ëë‹ˆë‹¤. ì´ì œ ì˜¨ë¼ì¸ìœ¼ë¡œ ë“¤ì–´ë³´ì…”ì•¼ê² ë„¤ìš”. 2026ë…„ 1ë¶„ê¸°ì¼ ë¿ì…ë‹ˆë‹¤. ì €í¬ì—ê²ŒëŠ” ì‘ì€ ë¶„ê¸° ì¤‘ í•˜ë‚˜ì£ . í•  ì¼ì´ ë§ìŠµë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” ë§ì€ ì¢‹ì€ ê²ƒë“¤ì„ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ì£¼ê°€ë¥¼ ë³´ê±°ë‚˜ ì—¬ëŸ¬ ìƒí™©ë“¤ì„ ë³¼ ë•Œ 'ë„ëŒ€ì²´ ìš°ë¦¬ê°€ ë­˜ í•˜ê³  ìˆëŠ” ê±´ê°€'ë¼ê³  ìë¬¸í•  ë•Œê°€ ìˆì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ íŒ€ì€ 5ë…„ì´ ë„˜ëŠ” ê¸°ê°„ ë™ì•ˆ ì •ë§ ë§ì€ ê²ƒë“¤ì„ í•¨ê»˜ ì´ë¤„ëƒˆìŠµë‹ˆë‹¤. ìºë‚˜ë‹¤ ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì„ ë§ ê·¸ëŒ€ë¡œ ì²˜ìŒë¶€í„° ì¬ê±´í•˜ë©´ì„œ ì‹œì„¤ì„ êµ¬ì¶•í•˜ê³ , ë¸Œëœë“œë¥¼ ë§Œë“¤ê³ , ì œí’ˆì„ ê°œë°œí•˜ê³ , ë‹¤ì–‘í•œ í’ˆì¢…ê³¼ ìœ ì „ìë¥¼ ì—°êµ¬í•˜ê³ , ìƒˆë¡œìš´ í˜ì‹  ê¸°ìˆ ë“¤ê³¼ ì•ìœ¼ë¡œ ë‚˜ì˜¬ ìƒˆë¡œìš´ í˜ì‹ ë“¤ì„ ê°œë°œí•˜ê³ , ì¸í”„ë¼ì™€ ì˜ì—… ë° ë§ˆì¼€íŒ… íŒ€ì„ êµ¬ì¶•í•´ì™”ìŠµë‹ˆë‹¤. ê°€ê²© ì••ë°•ì„ ê²ªê³ , ì½”ë¡œë‚˜19ë¥¼ ê²ªê³ , ë¶ˆë²• ì‹œì¥ì´ ê°€ì¥ í° ê²½ìŸì ì¤‘ í•˜ë‚˜ì¸ ìƒí™©ì„ í—¤ì³ë‚˜ê°€ë©´ì„œë„, ìºë‚˜ë‹¤ íŒ€ì´ í•´ë‚¸ ì„±ê³¼ì— ëŒ€í•´ ì •ë§ ë†’ì´ í‰ê°€í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. <br><br>êµ­ì œ ëŒ€ë§ˆì´ˆ ì‚¬ì—…ê³¼ ê´€ë ¨í•´ì„œë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì´ ì‚¬ì—…ì€ ê¸°ë³¸ì ìœ¼ë¡œ Tilray ì¸ìˆ˜ì™€ í•¨ê»˜ í†µí•©ë˜ì—ˆìœ¼ë©°, ì €ëŠ” ì´ ì‚¬ì—…ì—ì„œ ì—„ì²­ë‚œ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì¸ë„, ì¤‘ë™ ë“± ì—¬ëŸ¬ êµ­ê°€ì—ì„œ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆì™€ ê´€ë ¨ëœ ê¸°íšŒì— ëŒ€í•´ ë¬¸ì˜ë¥¼ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ë§ì€ êµ­ê°€ë“¤ì´ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆì˜ íš¨ëŠ¥ì„ ì¸ì‹í•˜ê³  ìˆìœ¼ë©°, í˜„ì¬ ì‹œì¤‘ì— ë‚˜ì™€ ìˆëŠ” ì˜ì•½í’ˆ ëŒ€ë¹„ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆì˜ íš¨ëŠ¥ê³¼ ì•½ë¬¼ ë¹„ìš© ì¸¡ë©´ì—ì„œì˜ ì´ì ì„ ê¹¨ë‹«ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ì—ê²ŒëŠ” í° ê¸°íšŒê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤.<br><br>ë¼ì¦ˆë‹ˆì‹œ ì˜¤ë¦¬(Rajnish Ohri)ê°€ ìƒˆë¡œìš´ ìœ ëŸ½ ì§€ì—­ ì±…ì„ìë¡œ í•©ë¥˜í•˜ì—¬ íŒ€ë“¤ì„ í†µí•©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ìºë‚˜ë‹¤ íŒ€ë“¤ê³¼ ë§ì€ í˜‘ë ¥ì„ í†µí•´ ì´ëŸ¬í•œ ì‚¬ì—…ë“¤ì„ í†µí•©í•˜ì—¬ ì‹œë„ˆì§€ì™€ ë¹„ìš© ì ˆê°ì„ ë‹¬ì„±í•˜ê³  ìˆìœ¼ë©°, ë§ì€ ë…¸í•˜ìš°ë¥¼ ì–»ê³  ìˆìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ ëŒ€ë§ˆì´ˆëŠ” ë³¸ì§ˆì ìœ¼ë¡œ ë†ì—…ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì„±ì¥ì„±, ìˆ˜í™•ëŸ‰, ê½ƒì˜ í¬ê¸°, íš¨ëŠ¥ ë“±ì´ ì¤‘ìš”í•œ ìš”ì†Œë“¤ì…ë‹ˆë‹¤. ì´ ì‚°ì—…ì€ ë¶ˆë²• ì‹œì¥ì—ì„œ ìˆ˜ë…„ê°„ í¼ì ¸ìˆë˜ ì‚°ì—…ì´ì§€ë§Œ, í•©ë²•í™”ëœ ì‹œì¥ì—ì„œì˜ ì‚°ì—…ì€ ì•„ë‹ˆì—ˆìŠµë‹ˆë‹¤. ì„±ì¥ê³¼ ì—°êµ¬ê°œë°œì´ ëª¨ë‘ ê²°í•©ëœ ì‚°ì—…ìœ¼ë¡œì„œ ì¡´ì¬í•´ì˜¨ ê²ƒë„ ì•„ë‹ˆê³ ìš”. ê°êµ­ ì •ë¶€ë“¤ì´ ê¸°íšŒë¥¼ ì¸ì‹í•˜ê³  ìˆìœ¼ë©°, ìêµ­ ì‹œë¯¼ë“¤ê³¼ í™˜ìë“¤ì´ ì´ëŸ¬í•œ ì œí’ˆì„ êµ¬ë§¤í•  ìˆ˜ ì—†ë„ë¡ í•˜ëŠ” ê²ƒì´ ë¬´ì—‡ì„ ì˜ë¯¸í•˜ëŠ”ì§€ ê¹¨ë‹«ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë˜í•œ ì •ë¶€ë“¤ì´ ì¸ì‹í•˜ê³  ìˆëŠ” ë˜ ë‹¤ë¥¸ ì ì€ ì„¸ìˆ˜ì…ë‹ˆë‹¤. ë¶ˆë²• ì‹œì¥ì„ í†µí•´ íŒë§¤ë˜ê³  ìˆëŠ” ì„¸ìˆ˜ë¥¼ ë†“ì¹˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ë§ì´ì£ . ì¼ì • ì¬ì¡°ì •ê³¼ ê´€ë ¨í•´ì„œ, íŠ¸ëŸ¼í”„ ëŒ€í†µë ¹ì´ ì—¬ëŸ¬ íŠ¸ìœ—ê³¼ ë°œì–¸ì„ í†µí•´ ì´ ë¶€ë¶„ì—ì„œ ë­”ê°€ ë³€í™”ê°€ ì¼ì–´ë‚˜ì•¼ í•œë‹¤ëŠ” ì ì„ ì¸ì‹í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì§€ë‚œì£¼ ë˜ëŠ” 2ì£¼ ì „ CBDì™€ ê³ ë ¹ìì— ê´€í•œ ê·¸ì˜ íŠ¸ìœ—ì„ ë³´ë©´, CBDì™€ THC ì œí’ˆì„ í†µì¦ê³¼ ë¶ˆì•ˆ ì™„í™” ëª©ì ìœ¼ë¡œ ì‚¬ìš©í•˜ê³  ìˆë‹¤ê³  ë§í•˜ëŠ” ì‚¬ëŒë“¤ì´ ì •ë§ ë§ê³ , ê·¸ íš¨ëŠ¥ì— ëŒ€í•´ì„œë„ ë“¤ë ¤ì£¼ê³  ìˆìŠµë‹ˆë‹¤. <br><br>í˜„ì¬ ì œí•œëœ ì£¼ì—ì„œ íŒë§¤ë˜ê³  ìˆëŠ” ë‹¹ì‚¬ì˜ ë¸íƒ€-9 ì œí’ˆë“¤ê³¼ ê·¸ì— ëŒ€í•œ ìˆ˜ìš”ë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë¸”ë ˆì–´ê°€ ìºë‚˜ë‹¤ ì‹œì¥ì—ì„œ 4ì²œë§Œ ë‹¬ëŸ¬ ì´ìƒì˜ ì‚¬ì—…ì„ êµ¬ì¶•í•œ ê²ƒì„ ë³´ì•˜ê³ , í˜„ì¬ëŠ” ëŒ€ë§ˆì´ˆ ë§¤ì¥ì—ì„œë§Œ íŒë§¤ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ì‹œ ë§í•˜ì§€ë§Œ, ê°€ì¥ ì €ë ´í•œ ê°€ê²©ëŒ€ëŠ” ì•„ë‹™ë‹ˆë‹¤. ë”°ë¼ì„œ ìŒë£Œ ì‚¬ì—…ì—ì„œ ì—„ì²­ë‚œ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ìŒë£Œ ì‚¬ì—…ê³¼ ê´€ë ¨í•´ì„œëŠ” í•´ì•¼ í•  ì¼ì´ ë§ìŠµë‹ˆë‹¤. 2020ë…„ SweetWater ì¸ìˆ˜ë¥¼ ì‹œì‘ìœ¼ë¡œ ì´ ì‚¬ì—…ì— ì§„ì¶œí–ˆê³ , Montaukì„ ì¸ìˆ˜í–ˆìœ¼ë©°, ABIë¡œë¶€í„° ë‹¤ë¥¸ ë¸Œëœë“œë“¤ê³¼ ì‚¬ì—…ì„ ì¸ìˆ˜í–ˆê³ , ê·¸ ë‹¤ìŒì—ëŠ” Molsonìœ¼ë¡œë¶€í„°ë„ ì‚¬ì—…ì„ ì¸ìˆ˜í–ˆìŠµë‹ˆë‹¤. í›Œë¥­í•œ ë¸Œëœë“œë“¤ì„ í™•ë³´í–ˆì§€ë§Œ, ì´ ëª¨ë“  ê²ƒì„ í•˜ë‚˜ë¡œ í†µí•©í•˜ëŠ” ê²ƒì€ ë§ì€ ì‘ì—…ì´ í•„ìš”í•©ë‹ˆë‹¤. ì‹œì„¤ë“¤ì„ í†µí•©í•˜ê³ , ë¹„ìš©ì„ ì ˆê°í•˜ê³ , ë§ˆì§„ì„ ê°œì„ í•˜ê³ , ì ì ˆí•œ ì‹œì„¤ì„ í™•ë³´í•˜ëŠ” ì¼ ë§ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ Tilrayê°€ í•˜ê³  ìˆëŠ” ì¼ì´ê³ , ì• í‹€ëœíƒ€ì˜ íŒ€ì´ ì´ ëª¨ë“  ê²ƒì„ í†µí•©í•˜ê¸° ìœ„í•´ ìˆ˜í–‰í•˜ê³  ìˆëŠ” ì‘ì—…ì…ë‹ˆë‹¤. <br><br>ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ë³€í™”ê°€ ì¼ì–´ë‚˜ê³  ìˆëŠ” í˜„ì¬ ìƒí™©ì—ì„œ ì‰¬ìš´ ì‚¬ì—…ì€ ì•„ë‹ˆì§€ë§Œ, ìš°ë¦¬ëŠ” ë‹¨ìˆœíˆ ë§¥ì£¼ ì‚¬ì—…ì´ ì•„ë‹Œ ìŒë£Œ ì‚¬ì—… ì „ë°˜ì— ê³„ì† ì°¸ì—¬í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì™€ ê´€ë ¨í•´ì„œ ìš°ë¦¬ê°€ ì‘ì—…í•˜ê³  ìˆëŠ” ì œí’ˆë“¤ì— ëŒ€í•œ ê´€ì‹¬ì´ ë§ìŠµë‹ˆë‹¤. ì¦ë¥˜ì£¼ ì‚¬ì—…ê³¼ ê´€ë ¨í•´ì„œëŠ”... ì €í¬ íŒ€ì€ ìœ í†µì—…ì²´ì¸ RNDCì™€ í˜‘ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. RNDCì™€ í•¨ê»˜ ì£¼ìš” ì‹œì¥ì— ì§„ì¶œí•˜ê¸° ìœ„í•œ ê³„íšì„ ì‹¤ì œë¡œ ìˆ˜ë¦½í–ˆìŠµë‹ˆë‹¤. ë„¤, ë²„ë²ˆ ì¹´í…Œê³ ë¦¬ëŠ” ì˜ˆì „ë³´ë‹¤ ë” ì–´ë ¤ìš´ ìƒí™©ì´ì§€ë§Œ, ë¸Œë ˆì¼„ë¦¬ì§€ ë²„ë²ˆì€ ì •ë§ ë§›ìˆëŠ” ì œí’ˆì´ê³  íŠ¹ì • ì‹œì¥ì—ì„œëŠ” ìˆ˜ìš”ê°€ ë†’ìŠµë‹ˆë‹¤. <br><br>ë™ì‹œì— ì €í¬ ë³´ë“œì¹´ëŠ” ìˆ˜ìš”ê°€ ë†’ê³ , ì§„ê³¼ ìƒˆë¡œ ì¶œì‹œí•œ ì¼ë¶€ ì œí’ˆë“¤ì€ ì •ë§ í›Œë¥­í•œ ì œí’ˆë“¤ë¡œ í˜ì‹ ì ì¸ ì²« ì‹œë„ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì œê°€ í•­ìƒ ë§ì”€ë“œë¦¬ëŠ” ì›°ë‹ˆìŠ¤ ì‚¬ì—…ì´ ìˆìŠµë‹ˆë‹¤. Jaredì™€ íŒ€ì´ ì›°ë‹ˆìŠ¤ ë¶€ë¬¸ì—ì„œ í•´ë‚¸ ì¼ì„ ë³´ë©´, ì¸ìˆ˜ ë‹¹ì‹œ ì•½ 500ë§Œ ë‹¬ëŸ¬ì—ì„œ 600ë§Œ ë‹¬ëŸ¬ì˜ ë§ˆì´ë„ˆìŠ¤ EBITDAì˜€ë˜ ê²ƒì´ ì˜¤ëŠ˜ë‚  ì™„ì „íˆ í„´ì–´ë¼ìš´ë“œë˜ì—ˆìŠµë‹ˆë‹¤. 1992ë…„, 93ë…„ë¶€í„° ì›°ë‹ˆìŠ¤ ì¹´í…Œê³ ë¦¬ì— ì°¸ì—¬í•´ì˜¨ ì‚¬ëŒìœ¼ë¡œì„œ ì´ëŸ° ì„±ì¥ì„ ëª©ê²©í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ìš°ë¦¬ê°€ ê³„ì† ì´ì•¼ê¸°í•˜ëŠ” ê²ƒì€ ì›°ë‹ˆìŠ¤ì…ë‹ˆë‹¤. íŠ¸ëŸ¼í”„ í–‰ì •ë¶€ì™€ ê´€ë ¨í•´ì„œ ì›°ë‹ˆìŠ¤ì™€ ì‹í’ˆ, ê·¸ë¦¬ê³  ì˜¤ëŠ˜ë‚  ì‹í’ˆì—ì„œ ìƒ‰ì†Œë¥¼ ì œê±°í•˜ê³  ê³ ë‹¨ë°±, ë‹¨ë°±ì§ˆ, ë‹¨ë°±ì§ˆ, ë‹¨ë°±ì§ˆì— ì§‘ì¤‘í•˜ëŠ” ê²ƒ ë§ì…ë‹ˆë‹¤. ê°€ì¥ ë†’ì€ ë‹¨ë°±ì§ˆ í•¨ëŸ‰ì„ ê°€ì§„ ê²ƒ ì¤‘ ì¼ë¶€ê°€ ë°”ë¡œ í—´í”„ ì‹í’ˆì¸ë°, ì´ëŠ” ì¬ë°°ë˜ëŠ” ì‹ë¬¼ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. <br><br>ìš°ë¦¬ëŠ” ë§¤ìš° ë‹¤ì–‘í•œ ì¹´í…Œê³ ë¦¬ì— ì§„ì¶œí•´ ìˆìŠµë‹ˆë‹¤. ë§¤ìš° ë…íŠ¹í•œ ì˜ì—­ë“¤ì— ìë¦¬ì¡ê³  ìˆì£ . ë¶€ì±„ë¹„ìœ¨(debt-to-equity) ì¸¡ë©´ì—ì„œ ìš°ë¦¬ ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ë³´ì‹œë©´ ë§¤ìš° ì¢‹ì€ ìƒíƒœì…ë‹ˆë‹¤. ë¶„ê¸°ë¥¼ 2ì–µ 6ì²œë§Œ ë‹¬ëŸ¬ì˜ í˜„ê¸ˆìœ¼ë¡œ ë§ˆê°í–ˆìŠµë‹ˆë‹¤. ë§ì€ ì¢‹ì€ ì¼ë“¤ì´ ì¼ì–´ë‚˜ê³  ìˆì§€ë§Œ, í•´ì•¼ í•  ì¼ë„ ë§ìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì„ ì‹¤í˜„í•˜ê³  ì†Œë§¤ë¥¼ ê±·ì–´ë¶™ì—¬ ì¼í•˜ëŠ” ìš°ë¦¬ íŒ€ì—ê²Œ ì •ë§ ê°ì‚¬ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ì „ ì„¸ê³„ì ìœ¼ë¡œ 2,500ëª…ì˜ ì§ì›ì´ ìˆì§€ë§Œ, ìš°ë¦¬ê°€ í•´ë‚´ì•¼ í•  ë§ì€ ì¼ë“¤ì„ ê³ ë ¤í•˜ë©´ ê²°ì½” ë§ì€ ì¸ì›ì´ ì•„ë‹™ë‹ˆë‹¤. <br><br>ì´ì œ ë§ˆë¬´ë¦¬í•˜ë©´ì„œ, ê²½ì²­í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì˜¤ëŠ˜ ë‚˜ì˜¨ ì¢‹ì€ ì˜ê²¬ë“¤ì´ ë§ìœ¼ë‹ˆ ë‹¤ì‹œ í•œ ë²ˆ ë“¤ì–´ë³´ì‹œê¸° ë°”ëë‹ˆë‹¤. ì§€ì›í•´ ì£¼ì‹œëŠ” ì£¼ì£¼ ì—¬ëŸ¬ë¶„ê»˜ë„ ê°ì‚¬ë“œë¦¬ë©°, ë‹¤ê°€ì˜¤ëŠ” ì£¼ì£¼ì´íšŒì—ì„œ ê¼­ íˆ¬í‘œì— ì°¸ì—¬í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. <br><br>ì¢‹ì€ ëª©ìš”ì¼ ë³´ë‚´ì‹œê³ , ìƒˆí•´ì— 2ë¶„ê¸° ì‹¤ì ê³¼ í•¨ê»˜ ë‹¤ì‹œ ëµ™ê¸°ë¥¼ ê¸°ëŒ€í•˜ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you. This concludes today's conference call. You may disconnect your lines at this time. Thank you for your participation.</td><td>**Operator:** ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ëŠìœ¼ì…”ë„ ë©ë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Here's a summary of the key points from the earnings call in Korean:<br><br>â€¢ ì¬ë¬´/ìš´ì˜ í˜„í™©:<br>- í¬ë¥´íˆ¬ê°ˆ í—ˆê°€ ì§€ì—° ë¬¸ì œê°€ í•´ê²°ë˜ê³  ìˆìœ¼ë©°, ìµœê·¼ 2ì£¼ê°„ ì§€ë‚œ 2ê°œì›”ë³´ë‹¤ ë” ë§ì€ í—ˆê°€ë¥¼ ë°›ìŒ<br>- ìºë‚˜ë‹¤ ì„±ì¸ìš© ì‹œì¥ì—ì„œ ê°€ê²©ì€ 2% ìƒìŠ¹, ë¬¼ëŸ‰ì€ ì‹œì¥ í‰ê·  ì´ìƒ ì„±ì¥<br>- ë¶„ê¸°ë§ í˜„ê¸ˆ ë³´ìœ ì•¡ 2ì–µ 6ì²œë§Œ ë‹¬ëŸ¬ ê¸°ë¡<br><br>â€¢ ì„±ì¥ ì „ëµ:<br>- ìœ ëŸ½ ì˜ë£Œìš© ëŒ€ë§ˆì´ˆ ì‚¬ì—…ì„ 2026ë…„ê¹Œì§€ 3ë°° ì„±ì¥ ëª©í‘œ<br>- CC Pharmaë¥¼ í†µí•´ ë…ì¼ ë‚´ 13,000ê°œ ì•½êµ­ ìœ í†µë§ í™œìš© ê³„íš<br>- í¬ë¥´íˆ¬ê°ˆ ì‹œì„¤ ê°€ë™ë¥ ì„ í˜„ì¬ 50%ì—ì„œ 100%ë¡œ í™•ëŒ€ ì¶”ì§„<br><br>â€¢ ë¦¬ìŠ¤í¬/ê¸°íšŒ ìš”ì¸:<br>- ë…ì¼ì˜ ìˆ˜ì… ì¿¼í„° ì œí•œì´ ë‹¨ê¸°ì  ì„±ì¥ì— ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆìŒ<br>- ë¯¸êµ­ ëŒ€ë§ˆì´ˆ ì¬ë¶„ë¥˜(Schedule III) ì‹œ ì‹œì¥ ì§„ì¶œ ê¸°íšŒ ëª¨ìƒ‰ ì¤‘<br>- ë§¥ì£¼ ì‚¬ì—… ë¶€ë¬¸ì˜ ìˆ˜ìµì„± ê°œì„ ì´ í•„ìš”í•œ ìƒí™©<br><br>ì „ë°˜ì ìœ¼ë¡œ ê²½ì˜ì§„ì€ ê·œì œ í™˜ê²½ ê°œì„ ê³¼ ìœ ëŸ½ ì‹œì¥ í™•ëŒ€ì— ëŒ€í•´ ê¸ì •ì ì¸ í†¤ì„ ë³´ì˜€ìœ¼ë‚˜, ì¼ë¶€ ì‚¬ì—… ë¶€ë¬¸ì˜ ìˆ˜ìµì„± ê°œì„ ì´ í•„ìš”í•œ ê²ƒìœ¼ë¡œ í‰ê°€ë¨.</p>
    <hr style="margin:50px 0;">
    
</body></html>